Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Specialised Therapeutics

Specialised Therapeutics

## Sitemaps

- [XML Sitemap](https://stabiopharma.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS](https://stabiopharma.com/new-chemotherapy-free-immunotherapy-combination-for-follicular-lymphoma-listed-on-the-pbs/) - Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a)
- [Operations and Forecasting Associate (Singapore)](https://stabiopharma.com/operations-and-forecasting-associate-singapore/) - About The Role Reporting to the Head of Quality and Technical Operations, you will be primarily responsible for managing operational and forecast/demand planning activities at third parties across Southeast Asia and Australia/New Zealand. Your key responsibilities will include: Run the monthly planning cycle including demand, supply and inventory reviews with all key stakeholders Lead the
- [New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia](https://stabiopharma.com/new-first-in-class-therapy-for-chronic-graft-versus-host-disease-approved-in-australia-1/) - NIKTIMVO® (axatilimab) has been registered for use in Australia by the TGA for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients 6 years and older weighing at least 40 kg
- [MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia](https://stabiopharma.com/minjuvi-tafasitamab-for-relapsed-or-refractory-follicular-lymphoma-approved-in-australia/) - Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been registered by the TGA for the treatment of Australian adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a)
- [New Combination Therapy for Advanced Small Cell Lung Cancer Approved in Australia and Singapore](https://stabiopharma.com/new-combination-therapy-for-advanced-small-cell-lung-cancer-approved-in-australia-and-singapore/) - Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), as a new first-line maintenance treatment option for adult patients in Australia and Singapore, who have been diagnosed with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer.
- [New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand](https://stabiopharma.com/new-breast-cancer-therapy-to-reduce-risk-of-recurrence-and-improve-disease-free-survival-now-available-in-thailand/) - Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX® (neratinib), for the first time. The launch of NERLYNX provides an important new treatment option for women diagnosed with human epidermal growth factor receptor 2 positive (HER2+) breast cancer. This follows the approval of NERLYNX by the Thai FDA in December 2024 as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitabine for the treatment of advanced or metastatic HER2+ breast cancer.
- [Company Update - Dec 2016](https://stabiopharma.com/company-update-dec-2016/) - See below, Specialised Therapeutics' Company Update for December 2016. To view this publication, move your mouse over the image below and click on the Fullscreen button in the top right corner to expand the window.
- [Company Update - Mar 2018](https://stabiopharma.com/company-update-mar-2018/) - See below, ST Asia's Company Update / Annual Report for 2017/18. To view this publication, move your mouse over the image below and click on the Fullscreen button in the top right corner to expand the window.
- [Company Update - Apr 2020](https://stabiopharma.com/company-update-apr-2020/) - See below, ST Asia's Company Update / Annual Report for 2018/19. To view this publication, click on the cover image below.
- [PBS Process Improvements Submission](https://stabiopharma.com/pbs-process-improvements-submission/) - By Carlo Montagner, CEO Specialised Therapeutics Australia Dear PBS Improvements Section, My name is Carlo Montagner and I am the Chief Executive Officer and co-founder of Australia’s largest independent pharmaceutical company, Specialised Therapeutics Australia (STA). We are a wholly family-owned Australian company, supplying specialist therapies and technologies to patients throughout Australia, as well as in
- [Transparency Reforms and Evaluation Support](https://stabiopharma.com/transparency-reforms-and-evaluation-support/) - Specialised Therapeutics Australia (STA) welcomes the opportunity to provide comments on the introduction of new measures to improve TGA transparency. STA was co-founded in 2008, with a commitment to commercialising specialist therapies and technologies that meet the unmet medical needs of all patients in its regions. Underpinning this endeavour is a foundation of innovation, which must be protected by regulatory transparency.
- [National Medicines Policy Review 2022](https://stabiopharma.com/national-medicines-policy-review-2022/) - ST has made several key recommendations to the Federal Government's National Medicines Policy Review, to improve timely and affordable access to specialist medicines. Click to read full submission.
- [Channel 7: November 2021](https://stabiopharma.com/channel-7-november-2021/) - The following tweet and story appeared on 7NEWS November 2021. A new treatment is now within reach for sufferers of a rare and incurable cancer. The new tablet has been listed on the PBS, helping buy patients precious time. Click here to watch: https://youtu.be/lDmbvaz1BMk @AKunowski #7NEWS
- [Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions](https://stabiopharma.com/st-extends-partnership-with-incyte/) - Singapore 11 June 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add
- [ABC News: May 2011](https://stabiopharma.com/abc-news-may-2011/) - The following news clip appeared on the ABC nationally in 2011. Click here to view.
- [Today Tonight Channel 7 Network: May 2012](https://stabiopharma.com/today-tonight-channel-7-network-may-2012/) - The following story appeared on the Channel 7 Network’s current affairs program Today Tonight in May, 2012. Click here to view.
- [Today Tonight Channel 7: March 2010](https://stabiopharma.com/today-tonight-channel-7-march-2010/) - The following story appeared on Channel 7’s current affairs program Today Tonight in March 2010. Click here to view.
- [ABC News 24: January 2014](https://stabiopharma.com/abc-news-24-january-2014/) - The following story appeared on the ABC in July 2014 announcing a PBS listing. Click here to view.
- [Channel 7 Adelaide: November 2014](https://stabiopharma.com/channel-7-adelaide-november-2014/) - The following story appeared on Channel 7 Adelaide November 2014. Click here to view.
- [Channel 10 News: November 2015](https://stabiopharma.com/channel-10-news-november-2015/) - The following story appeared on Channel 10 News nationally following a PBS listing. Click to view.
- [Video: Celebrating 10 Years](https://stabiopharma.com/video-celebrating-10-years/) - Celebrating 10 Years | Success is a culmination of our people, and our products. But it is patients who are at the heart of everything we do. Click on the link above to see a snapshot of what we’ve achieved in the last decade and some of the people who’ve made an impact along the way.
- [New Therapy for Children with Growth Hormone Deficiency Approved in Australia](https://stabiopharma.com/new-therapy-for-children-with-growth-hormone-deficiency-approved-in-australia/) - SKYTROFA® ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.1 Singapore 30 May 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new once-weekly injectable therapy for paediatric growth hormone deficiency (GHD).2 The Therapeutic Goods
- [First and Only Treatment for Chronic Hypoparathyroidism Approved in Australia](https://stabiopharma.com/first-and-only-treatment-for-chronic-hypoparathyroidism-approved-in-australia/) - YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval Singapore 21 February 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by
- [Specialised Therapeutics Signs Exclusive Agreement with Ascendis Pharma A/S for Distribution and Commercialisation of Three Endocrinology Therapies in Australia and Select South-East Asia Countries](https://stabiopharma.com/specialised-therapeutics-signs-exclusive-agreement-with-ascendis-pharma-a-s-for-distribution-and-commercialisation-of-three-endocrinology-therapies-in-australia-and-select-south-east-asia-countries/) - Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapies Two of the therapies are already internationally approved, the third is in development following successful Phase 2 data ST’s exclusive distribution agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore 8 January
- [New Therapy Options in Advanced Small Cell Lung Cancer (SCLC) Webinar](https://stabiopharma.com/new-therapy-options-in-advanced-small-cell-lung-cancer-sclc-webinar/) - These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch the complete webinar. SCLC Webinar Chapters Dr Paul Mitchell 2:31 to 3:03 Introduction: Dr Paul Mitchell 3:24 to 5:33 Background: Small Cell Lung Cancer 5.34 to 9.07 IMpower 133: Atezolizumab
- [Dr Paul Mitchell - Overview of the SCLC Treatment Landscape: the Australian Experience](https://stabiopharma.com/dr-paul-mitchell-overview-of-the-sclc-treatment-landscape-the-australian-experience/) - These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Paul Mitchell provide an overview of the SCLC treatment landscape in Australia. SCLC Webinar Chapters Introduction: Dr Paul Mitchell Background: Small Cell Lung Cancer IMpower 133: Atezolizumab + Carboplatin + etoposide in 1L
- [Dr Santiago Ponce-Aix - SCLC Post Progression Therapy Options](https://stabiopharma.com/dr-santiago-ponce-aix-sclc-post-progression-therapy-options/) - These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Santiago Ponce-Aix outline SCLC post-progression therapy options. SCLC Webinar Chapters Introduction for Dr Ponce-Aix New Standard of Care for ES-SCLC Retreatment with Platinum as 2nd line (>90 days) Immunotherapy in 2nd line Biomarker
- [Dr Amit Jain - Treatment Landscape and Challenges in Treating SCLC](https://stabiopharma.com/dr-amit-jain-treatment-landscape-and-challenges-in-treating-sclc/) - These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Amit Jain discuss the treatment landscape and challenges in treating SCLC. SCLC Webinar Chapters Introduction – Dr Amit Jain Paradigms in Treatment of Extensive SCLC SCLC – A Challenging Disease Chemotherapy in 1st and
- [Q&A Panel Discussion - New Therapy Options in Advanced Small Cell Lung Cancer (SCLC)](https://stabiopharma.com/qa-panel-discussion-new-therapy-options-in-advanced-small-cell-lung-cancer-sclc/) - These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch the Q&A panel discussion with Dr Paul Mitchell, Dr Santiago Ponce-Aix, Dr Amit Jain and Dr Tanujaa Rajasekaran. SCLC Webinar Chapters Q1: Does the 3-year OS data from CASPIAN influence the long-term efficacy perception of IO
- [Sarcoma Medical Education - Uterine Leiomyosarcoma (ULMS) Podcast](https://stabiopharma.com/sarcoma-medical-education-uterine-leiomyosarcoma-ulms-podcast/) - Sarcoma Medical Education - Uterine Leiomyosarcoma (ULMS) Podcast by Giovanni Grignani, M.D. This audio is intended for healthcare professionals for informative purposes only. Click play above to hear Giovanni Grignani M.D. provide an overview of Uterine Leiomyosarcoma (ULMS).
- [Sarcoma Medical Education - Liposarcoma Podcast](https://stabiopharma.com/sarcoma-medical-education-liposarcoma-podcast/) - Sarcoma Medical Education - Liposarcoma by Bernd Kasper, MD, PhD This audio is intended for healthcare professionals for informative purposes only. Click play above to hear Bernd Kasper MD, PhD provide an overview of Liposarcoma.
- [Specialised Therapeutics Signs Exclusive License Agreement with CanariaBio for New Ovarian Cancer Therapy](https://stabiopharma.com/specialised-therapeutics-signs-exclusive-license-agreement-with-canariabio-for-new-ovarian-cancer-therapy/) - First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 Phase 3 results expected in 2025 Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore and Seoul, South Korea, 13 October 2023: Independent
- [World Orphan Drug Alliance Welcomes Specialised Therapeutics](https://stabiopharma.com/world-orphan-drug-alliance-welcomes-specialised-therapeutics/) - SEA’s largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA) World Orphan Drug Alliance (WODA) now spans 152 countries. WODA offers a ‘one-stop’ solution for biotech companies
- [Specialised Therapeutics Acquires Commercialisation Rights to New Oral MND Therapy](https://stabiopharma.com/specialised-therapeutics-acquires-commercialisation-rights-to-new-oral-mnd-therapy/) - Singapore and Tilburg, Netherlands, August 28 2023: Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS) – the most common form of Motor Neurone Disease (MND) - in Australia and New Zealand. The therapy is
- [Global Sarcoma Therapy Now Listed on Pharmaceutical Benefits Scheme](https://stabiopharma.com/global-sarcoma-therapy-now-listed-on-pharmaceutical-benefits-scheme/) - YONDELIS® (trabectedin) now PBS listed for Australian patients Listing described as “wonderful news” for patients living with rare lipo and leiomyo sarcomas YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 Singapore, 31 July 2023: AUSTRALIAN cancer patients who have been diagnosed with rare soft tissue sarcomas will now
- [ST to Commercialise New Anti-PD1 Antibody](https://stabiopharma.com/st-to-commercialise-new-anti-pd1-antibody/) - Specialised Therapeutics Asia will partner with CTTQ-Akeso to commercialise a new immuno-oncology therapy in Australia, Singapore and across Southeast Asia.
- [Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies](https://stabiopharma.com/st-new-distributor-tafasitaman-pemigatinib-australia-new-zealand-singapore/) - Singapore, 22 October 2021: Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®). Under the
- [New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement](https://stabiopharma.com/new-drug-for-gastrointestinal-stromal-tumours-gist-to-be-launched-in-australia-new-zealand-and-south-east-asia-following-distribution-agreement/) - Singapore, 06 November 2020: A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia, New Zealand and in some parts of South East Asia, following an exclusive distribution agreement. Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an agreement with US-based Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialise the
- [Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug](https://stabiopharma.com/specialised-therapeutics-signs-exclusive-deal-for-new-haematology-drug/) - Singapore, 18 December, 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome (MDS). The drug, known as rigosertib, is currently in a Phase 3 clinical trial to assess the efficacy and
- [Building from a Solid Foundation: The Future of MedTech in Australia](https://stabiopharma.com/building-from-a-solid-foundation-the-future-of-medtech-in-australia-3/) - ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. Turn to pages 16 and 17 where CEO Carlo Montagner discusses our business model, licensing strategy and future plans. Click on the magazine below to read the article.
- [Building from a Solid Foundation: The Future of MedTech in Australia](https://stabiopharma.com/building-from-a-solid-foundation-the-future-of-medtech-in-australia/) - ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. Turn to pages 16 and 17 where CEO Carlo Montagner discusses our business model, licensing strategy and future plans. Click on the magazine below to read the article.
- [Patient Experience – Small Cell Lung Cancer](https://stabiopharma.com/patient-experience-small-cell-lung-cancer/) - 57 year old Lay Har has never been a smoker and has always considered herself relatively healthy, was shocked when she was diagnosed with Stage 4 Small Cell Lung Cancer in April this year, after experiencing some “discomfort” in her chest. She was scared by her diagnosis but has found support from fellow patients and
- [Lymphoma Therapy Now Approved for Australian Patients with Diffuse Large B-cell Lymphoma](https://stabiopharma.com/lymphoma-therapy-now-approved-for-australian-patients-with-diffuse-large-b-cell-lymphoma/) - MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration1 Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses2 Singapore, 28 June 2023: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that a new therapy to treat the most common type of non-Hodgkin lymphoma in
- [Channel 7: August 2023](https://stabiopharma.com/channel-7-august-2023/) - The following story appeared on 7NEWS August 2023. When nature delivers new medicine: Our soft tissue sarcoma therapy Yondelis® (trabectedin) has this month been listed on the Pharmaceutical Benefits Scheme for patients with advanced liposarcoma and leiomyosarcoma, but you may be surprised where scientists originally sourced this novel compound. https://www.youtube.com/watch?v=uHBQjEJ090Y
- [Breast Cancer Awareness Month: Meet the Specialist](https://stabiopharma.com/breast-cancer-awareness-month-meet-the-specialist/) - Consultant Clinical Oncologist Dr Aqilah Othman says an ageing population, fewer and later pregnancies, a lack of physical activity, obesity and poor dietary habits may be contributing to a rising incidence of new breast cancer cases across Southeast Asia. To mark Breast Cancer Awareness Month 2023, the Sunway Medical Centre oncologist discusses the incidence of
- [Cholangiocarcinoma: Understanding This Rare Liver Disease](https://stabiopharma.com/cholangiocarcinoma-understanding-this-rare-liver-disease/) - This article is contributed by Dr Choo Su Pin, a senior medical oncologist at Curie Oncology who specialises in gastrointestinal cancers.
- [Specialised Therapeutics Australia Extends Collaboration with Swiss Helsinn Group](https://stabiopharma.com/specialised-therapeutics-australia-extends-collaboration-with-swiss-helsinn-group/) - Melbourne, Australia and Lugano, Switzerland, 10 August 2011: Melbourne bio-pharmaceutical company Specialised Therapeutics Australia plans to further expand its oncology portfolio, to include a new product for the prevention of chemotherapy-induced nausea and vomiting (CINV). The Australian company has signed a letter of intent with its Swiss partner, Helsinn Group, to in-license Helsinn’s new compound for
- [Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)](https://stabiopharma.com/helsinn-grants-specialised-therapeutics-australia-sta-rights-to-anamorelin-a-first-in-class-compound-to-treat-cachexia-anorexia-related-to-non-small-cell-lung-cancer-nsclc/) - Lugano, Switzerland and Melbourne, Australia, October 15th, 2012 – Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia. This condition is a serious multifactorial disorder which involves muscle wasting and metabolic impairment and commonly affects patients with advanced cancer. STA has reached agreement with Swiss pharmaceutical company Helsinn Healthcare to in-license the novel ghrelin receptor agonist anamorelin for both Australia and New Zealand.
- [Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients](https://stabiopharma.com/specialised-therapeutics-australia-partners-with-genomic-health-inc-to-deliver-novel-genomic-test-to-breast-cancer-patients/) - Melbourne, Australia January 7, 2014: Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc. (NASDAQ: GHDX). STA has struck an agreement to represent the important diagnostic technology
- [ARIAD Announces Commercial Agreement for ICLUSIG® (ponatinib) in Australia](https://stabiopharma.com/ariad-announces-commercial-agreement-for-iclusig-ponatinib-in-australia/) - Melbourne, Australia January 28, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias. Under the terms of the agreement, STA will be responsible for obtaining marketing authorization and
- [Specialised Therapeutics Asia to Distribute Novel Multiple Myeloma Drug APLIDIN® in South East Asia, Australia and New Zealand](https://stabiopharma.com/specialised-therapeutics-asia-to-distribute-novel-multiple-myeloma-drug-aplidin-in-south-east-asia-australia-and-new-zealand/) - SINGAPORE and MELBOURNE, Australia, Feb. 2, 2016 /PRNewswire/ -- International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. Under the terms of the latest agreement, ST Asia will be allowed marketing and distribution rights
- [Aeterna Zentaris and Specialised Therapeutics Asia Sign Exclusive License Agreement for the Potential Marketing of Zoptrex™ in Australia and New Zealand](https://stabiopharma.com/aeterna-zentaris-and-specialised-therapeutics-asia-sign-exclusive-license-agreement-for-the-potential-marketing-of-zoptrex-in-australia-and-new-zealand/) - Charleston, South Carolina and Singapore, October 12, 2016: Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) and Specialised Therapeutics Asia (“STA”) today announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the territories of Australia and New Zealand (the “Territory”). Zoptrex™, a novel synthetic
- [Specialised Therapeutics Asia to License a Promising Anti-Cancer Compound Lurbinectedin (PM1183) for South East Asia, Australia and New Zealand](https://stabiopharma.com/specialised-therapeutics-asia-to-license-a-promising-anti-cancer-compound-lurbinectedin-pm1183-for-south-east-asia-australia-and-new-zealand/) - SINGAPORE and MELBOURNE, Australia, May 17, 2017: International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) is set to commercialise a promising new anti-cancer drug throughout South East Asia, after signing a second major licensing deal with European pharmaceutical company PharmaMar. The latest agreement allows ST Asia marketing and distribution rights to new anti-cancer compound lurbinectedin
- [New Early-Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia following License Deal](https://stabiopharma.com/new-early-breast-cancer-drug-to-be-made-available-in-australia-new-zealand-and-south-east-asia-following-license-deal/) - Singapore, 23 November 2017: A NEW breast cancer drug shown to reduce the risk of cancer recurrence will soon be made available in Australia, New Zealand and throughout South-East Asia, following a key license deal between Specialised Therapeutics Asia (ST Asia) and US biopharmaceutical company Puma Biotechnology, Inc. (NASDAQ: PBYI). Under the terms of the
- [STA to market sarcoma drug in Australia, New Zealand and SE Asia Following License Deal](https://stabiopharma.com/sta-to-market-sarcoma-drug-in-australia-new-zealand-and-se-asia-following-license-deal/) - Singapore and Melbourne, Australia, 14 October 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia, New Zealand and throughout SE Asia. Under the terms of the agreement, STA will provide the marine-derived compound YONDELIS (trabectedin) to patients
- [From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win](https://stabiopharma.com/from-big-pharma-to-small-starts-risking-it-all-on-a-life-saving-cancer-drug-to-win/) - SARAH-JANE TASKER | THE AUSTRALIAN| MARCH 19, 2016 12:00AM From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win Bozena Zembrzuski and Carlo Montagner reflect on their decision to found Specialised Therapeutics and bring Abraxane to Australia. Picture: Aaron Francis After years working for big pharma in the US,
- [Thailand Office Opened](https://stabiopharma.com/new-thailand-office-opened/) - Specialised Therapeutics is thrilled to announce the official opening of its Thailand office, as we continue our mission to provide specialist therapies to patients across South East Asia. We are determined to ensure our medicines reach as many eligible patients as possible - particularly in oncology, with almost 200,000 Thai residents diagnosed with cancer every year (*Globocan 2020).
- [Collaborate: We Work Closely with Global Business Partners](https://stabiopharma.com/collaborate-we-work-closely-with-global-business-partners/) - Collaborate: We work closely with our global business partners and take care of their products as if they were our own. We also manage complex regulatory landscapes in our regions. Here's Ulrich Kosciessa from photonamic GmbH discussing our successful partnership. Click on the image above to view.
- [10 Years of Partnering](https://stabiopharma.com/10-years-of-partnering/) - ST began with a single drug and a single global partner in 2008. Today, our company collaborates with several high-class biotechnology and pharma partners around the globe. All have been prudently selected because their products fulfill an unmet medical need. In 10 years, ST has executed a strategy of identifying promising mid-to-late-stage compounds for
- [Meet the Specialist: Breast Cancer Oncologist Dr Khoo Kei Siong](https://stabiopharma.com/breast-cancer-oncologist-dr-khoo-kei-siong/) - Singapore breast cancer oncologist Dr Khoo Kei Siong says “changes in dietary habits, life style and reproductive patterns” are the most likely reasons breast cancer diagnoses are rising steadily in the region – with a more than three-fold increase since the late 1960s. But there is good news, with the prognosis for these women “improving significantly”.
- [Julie's Ordeal with Oropharyngeal Cancer and Oral Mucositis](https://stabiopharma.com/julies-ordeal-with-oropharyngeal-cancer-and-oral-mucositis/) - “I was diagnosed in 2013. Most throat cancers are caused by alcohol and tobacco, but mine was caused by the human papillomavirus (HPV). The primary site was on my tonsils, on the back of my tongue and on the side of my throat. My treatment was 30 consecutive days of radiation therapy. This meant a
- [Sarcoma Awareness Month: Karen's Story](https://stabiopharma.com/sarcoma-awareness-month-karens-story/) - Karen Lurati was in her late forties, juggling a busy career and family when she noticed she was steadily gaining weight. Because she was also experiencing other symptoms like tiredness and hot flushes, she put it down to menopause. It was only when she felt an increased heaviness, or pressure on her pelvic floor, that
- [New Therapy for Rare Gastrointestinal Stromal Tumours Approved in Singapore](https://stabiopharma.com/new-therapy-for-rare-gastrointestinal-stromal-tumours-approved-in-singapore/) - Singapore’s Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 Singapore, 8 May 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is
- [International Women’s Day 2023](https://stabiopharma.com/international-womens-day-2023-2/) - ST Medical Director Paula Fenwick knew from a young age in South Africa that a career in science beckoned. But there were no scientists in her family and her parents were initially reluctant to let her attend university. Her godmother stepped in and helped her blaze a trail that has taken her around the world and allowed her to mentor other young women seeking a STEM career. To mark #IWD23, Paula reflects on her career journey.
- [International Women’s Day 2023](https://stabiopharma.com/international-womens-day-2023/) - Born and raised in cities throughout North India, 28-year-old Prakriti Langer arrived in Australia five years ago to pursue a Masters in Biotechnology. After graduating, “I knew I wanted to gain global exposure. I chose Australia, which is a thriving hub for life sciences.”
- [Global Sarcoma Therapy Now Approved for New Zealand Patients](https://stabiopharma.com/global-sarcoma-therapy-now-approved-for-new-zealand-patients/) - Singapore and Auckland, New Zealand, 17 February 2023: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand.
- [Pharma Dispatch: 20 January, 2023](https://stabiopharma.com/biopharmadispatch-20-january-2023/) - Pharma Dispatch 20 January 2023 New Zealand Approval for Specialised Therapeutics' Cancer Therapy Specialised Therapeutics Asia has announced that its therapy to treat rare gastrointestinal stromal tumours, QINLOCK (ripretinib), has been approved for use in New Zealand and will now be considered for funding by PHARMAC. The regulator, Medsafe, has approved QINLOCK for
- [Pharma in Focus: 20 January, 2023](https://stabiopharma.com/pharma-in-focus-20-january-2023/) - PHARMA IN FOCUS By Tiffany Walker 20 January 2023 ST Notches Another Win Specialised Therapeutics (ST) has scored approval for Qinlock in New Zealand, marking the second of five regions that the company has rights to commercialise the advanced gastrointestinal stromal tumour (GIST) treatment. The Singapore headquartered company was established to commercialise new therapies and
- [New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in Malaysia](https://stabiopharma.com/new-early-breast-cancer-drug-to-reduce-risk-of-recurrence-or-death-now-available-in-malaysia/) - Singapore, 29 March 2022: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now available in Malaysia. The drug, NERLYNX® (neratinib) is an oral medication taken for 12 months by women who have been diagnosed with early stage HER2-positive (HER2+) breast cancer and who have received prior trastuzumab-based therapy.
- [New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients](https://stabiopharma.com/new-therapy-to-treat-rare-gastrointestinal-stromal-tumour-approved-for-new-zealand-patients/) - Singapore and New Zealand, 20 January 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now been approved in New Zealand.
- [‘Great Relief’ for Australian Patients with New Therapy to Treat Rare GIST Cancers Listed on PBS](https://stabiopharma.com/new-therapy-to-treat-rare-gist-cancers-listed-on-pbs/) - QINLOCK® (ripretinib) now PBS listed for Australian patients QINLOCK is the first new reimbursed therapy to treat advanced GIST in more than a decade Leading Australian oncologist says the listing will help to “buy patients more time” Data shows QINLOCK reduces risk of disease progression by 85%1, 2 14 November, 2021: AUSTRALIAN cancer patients
- [New Treatment for Rare Cancer Cholangiocarcinoma Approved in Australia](https://stabiopharma.com/new-treatment-for-rare-cancer-cholangiocarcinoma-approved-in-australia/) - Melbourne, Australia 15 September 2022: A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia.
- [Meet the Specialist: Dr Toh Chee Keong](https://stabiopharma.com/meet-the-specialist-dr-toh-chee-keong/) - Low-dose thoracic CT screening of chronic and former smokers aged over 50 would help to detect early lung cancers and save lives, according to Singapore lung cancer expert Dr Toh Chee Keong. The leading oncologist says he would like to see a subsidised program for early detection – much like the mammogram screening program for breast cancer.
- [When ‘one in a million’ is not uncommon: Dr Jason Chan discusses rare cancers in Singapore](https://stabiopharma.com/when-one-in-a-million-is-not-uncommon-dr-jason-chan-discusses-rare-cancers-in-singapore/) - Rare cancers in Singapore are not so rare, according to medical oncologist Dr Jason Chan, who specialises in treating patients with less common oncologic variations. He says up to 7000 Singapore cancer patients are diagnosed every year with one of about 200 rare cancer variations – which means there are fewer treatment options and scarce information.
- [Meet the Singapore Specialist: Medical Oncologist Dr Lynette Ngo](https://stabiopharma.com/meet-the-singapore-specialist-medical-oncologist-dr-lynette-ngo/) - While 1 in 13 women Singaporean women will be diagnosed with breast cancer in their lifetime – the highest incidence in South-East Asia - senior oncologist Dr Lynette Ngo wants her patients to know that five-year survival rates “are better than they have ever been”, even for those with advanced cancers.
- [Philanthropy: ONJ Cancer and Wellness Centre](https://stabiopharma.com/philanthropy-onj-cancer-and-wellness-centre/) - Our philanthropic philosophy was born well before we formally established the Montagner-Zembruzuski Family Foundation. It was while living and working in the United States in senior pharmaceutical roles that we saw and were inspired by this spirit of giving in action. When we heard the Olivia Newton-John Cancer and Wellness Centre was being built in
- [SSO 2022: Professor Adam Brufsky](https://stabiopharma.com/sso-2022-professor-adam-brufsky/) - Adam M. Brufsky, MD, PhD Speaking at the Singapore Society of Oncology July 2022 on 'Available Therapeutic Options for the Management of HER2-Positive Metastatic Breast Cancer: 2nd Line and Beyond'.
- [New Therapy for Rare Gastrointestinal Stromal Tumours Accepted in Singapore for Regulatory Evaluation](https://stabiopharma.com/new-therapy-for-rare-gastrointestinal-stromal-tumours-accepted-in-singapore-for-regulatory-evaluation/) - Singapore, 12 July 2022: A novel therapy to treat rare gastrointestinal stromal tumours (GIST) has been accepted for evaluation by Singapore’s Health Sciences Authority.
- [New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in the Philippines](https://stabiopharma.com/new-early-breast-cancer-drug-to-reduce-risk-of-recurrence-or-death-now-available-in-the-philippines/) - Singapore, 8 July 2022: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now approved by the Food and Drug Administration of the Philippines. The drug, NERLYNX (neratinib) is an oral medication taken daily for 12 months by women who have been diagnosed with early-stage HER2-positive (HER2+) breast cancer and who have received prior trastuzumab-based therapy.
- [Specialised Therapeutics Appoints New Logistics Partner](https://stabiopharma.com/specialised-therapeutics-appoints-new-logistics-partner/) - Singapore, 4 July 2022: International biopharmaceutical company Specialised Therapeutics (ST) has struck an important agreement with highly recognised logistics partner Healthcare Logistics (HCL) to store and distribute its growing portfolio of specialist healthcare products in Australia.
- [Introducing GIST and Sarcoma Specialist Dr Richard Quek](https://stabiopharma.com/introducing-gist-and-sarcoma-specialist-dr-richard-quek/) - Dr Richard Quek says he has “the best job in the world”. The Singapore based specialist in both GIST and sarcoma cancers believes it is a great privilege to care for patients during what is often a difficult cancer journey. “I enjoy the deep interactions I have with my patients and I am honored that
- [Meet the Singapore Specialist: Medical Oncologist Dr Tan Yew Oo](https://stabiopharma.com/meet-the-specialist-singapore-medical-oncologist-dr-tan-yew-oo/) - He was one of Singapore’s first medical oncologists and now in his late seventies, Dr Tan Yew Oo is one of the oldest practising oncologists, seeing cancer patients daily and striving to make a difference.
- [MedNews: 9 March, 2022](https://stabiopharma.com/mednews-9-march-2022/) - At homegrown pharma company Specialised Therapeutics, 82 per cent of employees are women, three in every four employees is aged over 40, and nine of the 12 executive team members is female. Age, gender, and ethnicity are not a consideration when hiring, says CEO Carlo Montagner, who instead employs people that best fit with the values of the business he co-founded with his wife, Bozena Zembrzuski.
- [The Australian: 19 March, 2016](https://stabiopharma.com/the-australian-19-march-2016/) - THE AUSTRALIAN By Sarah-Jane Tasker 19 March 2016 From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win Bozena Zembrzuski and Carlo Montagner reflect on their decision to found Specialised Therapeutics and bring Abraxane to Australia. Picture: Aaron Francis After years working for big pharma in the
- [Pharma Dispatch: 5 April, 2017](https://stabiopharma.com/pharma-dispatch-5-april-2017/) - Pharma Dispatch 5 April 2017 Specialised Therapeutics Relaunches Product for Cancer Patients Independent pharmaceutical company Specialised Therapeutics Asia has relaunched a product used to relieve the pain of oral mucositis, a condition that can affect cancer patients undergoing chemotherapy and/or radiotherapy. CEO Carlo Montagner said GELCLAIR was a welcome inclusion to the company’s
- [GLIOLAN® Granted Orphan Drug Status by the Therapeutic Goods Administration](https://stabiopharma.com/gliolan-granted-orphan-drug-status-by-the-therapeutic-goods-administration/) - Melbourne, Australia April 2012: A drug which aids neurosurgeons to better visualise and more completely remove malignant brain tumours has been granted orphan drug status by the Therapeutic Goods Administration (TGA). The drug, Gliolan, is currently in-licensed by Melbourne biopharmaceutical company, Specialised Therapeutics Australia (STA) and is currently only available to neurosurgeons via the federal
- [ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients](https://stabiopharma.com/abraxane-demonstrates-significant-improvement-in-progression-free-survival-compared-to-standard-chemotherapy-in-advanced-melanoma-patients-3/) - MELBOURNE, Australia – October 25, 2012 – Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE® (nanoparticle albumin-bound paclitaxel).
- [ABRAXANE® Plus Gemcitabine Improves Survival in Phase III Study of Patients with Advanced Pancreatic Cancer](https://stabiopharma.com/abraxane-plus-gemcitabine-improves-survival-in-phase-iii-study-of-patients-with-advanced-pancreatic-cancer/) - MELBOURNE, Australia – January 23, 2013 – Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving
- [New ‘Superbug’ Antibiotic Approved for Use in Australia](https://stabiopharma.com/new-superbug-antibiotic-approved-for-use-in-australia/) - MELBOURNE, Australia – April 26, 2013 – An effective new antibiotic designed to specifically treat the common superbug* infection Clostridium difficile-associated diarrhoea will be available to patients in Australia from 14th May 2013. Melbourne biopharmaceutical company Specialised Therapeutics Australia Pty Ltd (STA) has received Therapeutic Goods Administration (TGA) approval to market the drug DIFICID (fidaxomicin) in Australia.
- [Specialised Therapeutics Australia Receives Therapeutic Goods Administration Approval for Brain Tumour Visualisation Drug - GLIOLAN®](https://stabiopharma.com/specialised-therapeutics-australia-receives-therapeutic-goods-administration-approval-for-brain-tumour-visualisation-drug-gliolan/) - Melbourne, Australia and Hamburg, Germany, November 2013: A novel drug which assists neurosurgeons to better visualise and remove malignant brain tumours has been approved by the Therapeutic Goods Administration (TGA). Until now, GLIOLAN (aminolevulinic acid HCl) has only been available via the Federal Government’s Special Access Scheme (SAS). It will now be made widely available for
- [STA to License New Drug – ILUVIEN® – to Improve Vision in Patients with Diabetes-Induced Vision Loss](https://stabiopharma.com/sta-to-license-new-drug-iluvien-to-improve-vision-in-patients-with-diabetes-induced-vision-loss/) - Melbourne, Australia and Atlanta, Georgia, 28 April 2014: Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences. (NASDAQ: ALIM). The exclusive agreement enables STA to distribute
- [STA: License Agreement with PharmaMar to Market, Distribute Oncology Drug APLIDIN® (plitidepsin) in AU and NZ](https://stabiopharma.com/sta-license-agreement-with-pharmamar-to-market-distribute-oncology-drug-aplidin-plitidepsin-in-au-and-nz/) - Melbourne, Australia, 20 August 2015: Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN® (plitidepsin) in Australia and New Zealand. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations
- [Cutting Edge Breast Cancer Test ‘Should Be Reimbursed’ – Medical Experts](https://stabiopharma.com/cutting-edge-breast-cancer-test-should-be-reimbursed-medical-experts/) - Melbourne, Australia, 3 September 2015: A BREAKTHROUGH genetic test that could spare thousands of Australian women with early stage breast cancer from chemotherapy and its toxic side effects will be considered for reimbursement later this year. The multi-gene test, known as the Oncotype DX® Breast Cancer Assay, predicts a patient’s likely benefit from chemotherapy and the overall risk
- [Specialised Therapeutics’ Breakthrough Brain Tumour Visualisation Drug GLIOLAN® Approved for Use in New Zealand](https://stabiopharma.com/specialised-therapeutics-breakthrough-brain-tumour-visualisation-drug-gliolan-approved-for-use-in-new-zealand/) - Melbourne, Australia, 17 September 2015: A NOVEL drug which helps neurosurgeons to better visualise and remove malignant brain tumours has been approved for marketing and distribution in New Zealand by Medsafe. The drug, GLIOLAN (aminolevulinic acid HCl), assists neurosurgeons to better visualise and more completely remove malignant brain tumours (gliomas) by causing them to become
- [TAILORx Trial Finds 99 Percent of Women with Low Oncotype DX Recurrence Score® Results are Free of Breast Cancer Recurrence After Five Years of Hormone Therapy Alone](https://stabiopharma.com/tailorx-trial-finds-99-percent-of-women-with-low-oncotype-dx/) - MELBOURNE, Australia, REDWOOD CITY, Calif, USA and GENEVA, Switzerland, 29 September 2015: Specialised Therapeutics Australia and Genomic Health announce the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial, designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI). The study, published online in
- [Specialized Therapeutics Grants Sublicense for Anti-Emetic Products to Mundipharma for Australia and New Zealand Anti-emetic Products Covered Under the Sublicense Agreement Include ALOXI® (palonosetron hydrochloride) and AKYNZEO® (netupitant/palonosetron).](https://stabiopharma.com/specialized-therapeutics-grants-sublicense-for-anti-emetic-products-to-mundipharma-for-australia-and-new-zealand-anti-emetic-products-covered-under-the-sublicense-agreement-include-aloxi-palono/) - Melbourne, Australia, 7 March 2016: Specialized Therapeutics Pty Ltd and Mundipharma Pty Limited today announce a sublicense agreement enabling Mundipharma to assume all commercialisation responsibilities for the anti-emetic products ALOXI® (palonosetron hydrochloride) and AKYNZEO® (netupitant/palonesetron). Under the terms of the arrangement, Specialized Therapeutics grants Mundipharma exclusive marketing, promotion, distribution and sales rights for the anti-nausea and vomiting pharmaceutical
- [Novel Multiple Myeloma Drug APLIDIN® Shows Positive Results in Pivotal Phase 3 Study](https://stabiopharma.com/novel-multiple-myeloma-drug-aplidin-shows-positive-results-in-pivotal-phase-3-study/) - Singapore, Madrid and Melbourne, Australia, 31 March 2016: International biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST Asia) will seek regulatory approvals for novel multiple myeloma drug Aplidin® (plitidepsin) following the release of positive results in a pivotal Phase 3 study.
- [Specialised Therapeutics Strikes Deal with World Courier Australia to Manage Logistics for Specialty Pharma Products](https://stabiopharma.com/specialised-therapeutics-strikes-deal-with-world-courier-australia-to-manage-logistics-for-specialty-pharma-products/) - Melbourne, Australia 16 June 2016: International biopharmaceutical company Specialised Therapeutics Australia has struck an important agreement with global logistics partner World Courier Australia (WCA) to manage and handle its growing portfolio of specialist healthcare products around the country.
- [Study Finds ABRAXANE Combination Chemotherapy is Superior to Other Chemotherapy Combinations in Women with Metastatic Triple Negative Breast Cancer](https://stabiopharma.com/study-finds-abraxane-combination-chemotherapy-is-superior-to-other-chemotherapy-combinations-in-women-with-metastatic-triple-negative-breast-cancer/) - Melbourne, Australia and Singapore, 23 December 2016: An international study has found that women with metastatic triple-negative breast cancer (mTNBC) demonstrated improved progression-free survival when treated with a combination of ABRAXANE (nanoparticle albumin-bound paclitaxel) and carboplatin, compared to other chemotherapy combinations.
- [Specialised Therapeutics to Remove Territory Sales Incentives from Staff Bonus Plan](https://stabiopharma.com/specialised-therapeutics-to-remove-territory-sales-incentives-from-staff-bonus-plan/) - Melbourne, Australia, 1 February 2017: International biopharmaceutical company Specialised Therapeutics will today launch a new company business model, as part of a bold plan to improve relationships with healthcare professionals. Under this plan, sales teams will no longer be paid bonuses based on the number of prescriptions written. Instead, in field representatives will be rewarded
- [Specialised Therapeutics to Relaunch GELCLAIR in Australia](https://stabiopharma.com/specialised-therapeutics-to-relaunch-gelclair-in-australia/) - Singapore and Melbourne, Australia, 4 April, 2017: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) will today relaunch a product used to relieve the pain of oral mucositis, a condition that can affect cancer patients undergoing chemotherapy and/or radiotherapy. GELCLAIR is a bio-adherent oral gel that works by creating a protective film in the mouth,
- [Brain Tumour Visualisation Drug GLIOLAN to be Listed on NZ Hospital Medicines List from 1 June](https://stabiopharma.com/brain-tumour-visualisation-drug-gliolan-to-be-listed-on-nz-hospital-medicines-list-from-1-june/) - Singapore, Melbourne and Auckland, 28 April 2017: A NOVEL drug which ‘lights up’ malignant brain tumours to help surgeons more thoroughly resect the cancer tissue will be widely available to New Zealand patients from 1 June, after a leading neurosurgeon applied for its reimbursement. The drug, GLIOLAN (aminolevulinic acid HCl), assists neurosurgeons to more completely remove malignant
- [Brain Surgery Breakthrough: New Zealand Neurosurgeon Pioneers NZ-First Technique](https://stabiopharma.com/brain-surgery-breakthrough-new-zealand-neurosurgeon-pioneers-nz-first-technique/) - Auckland, New Zealand, 31 May 2017: A 33 year old Wellington mother of two has become the first New Zealand patient to be treated with a novel brain cancer visualisation drug that ‘lights up’ tumours during surgery to enable more complete removal of the malignant tissue. GLIOLAN® (aminolevulenic acid: ALA) is taken as a drink three
- [Federal Government Rejects Funding Bid for Novel Breast Cancer Test That May Spare Women from Chemotherapy](https://stabiopharma.com/federal-government-rejects-funding-bid-for-novel-breast-cancer-test-that-may-spare-women-from-chemotherapy/) - Oncotype DX® breast cancer assay may spare thousands of women from chemotherapy Medical Services Advisory Committee has now rejected five funding applications for Oncotype DX Melbourne, Australia, 4 October 2017: THE Federal Government’s peak advisory committee for Medicare funding has rejected calls from doctors, patients and the pharma industry to fund a novel breast cancer test
- [Specialised Therapeutics Asia Initiates Early Access Program for Neratinib](https://stabiopharma.com/specialised-therapeutics-asia-initiates-early-access-program-for-neratinib/) - Singapore, 5 April 2018: Specialised Therapeutics Asia today announces the initiation of an early access program for neratinib, an extended adjuvant treatment for early-stage HER2-positive (HER2+) breast cancer. Under this Special Access Program (SAP) select patients in Australia will be provided access to the medicine, where appropriate and when permitted by relevant regulatory authorities. The
- [Specialised Therapeutics Celebrates 10 Years and Unveils Expansion Plan](https://stabiopharma.com/specialised-therapeutics-celebrates-10-years-and-unveils-expansion-plan/) - Melbourne, Australia 27 August 2018: Privately-held pharmaceutical company Specialised Therapeutics Australia will today mark its 10th anniversary, unveiling new Australian headquarters and a business plan to drive healthcare innovation over the next decade. The company, which was founded ten years ago by pharmaceutical expats Carlo Montagner and Bozena Zembrzuski with a single chemotherapy product, has
- [Specialised Therapeutics to Collaborate with Pharmacy Phusion to Improve Patient Outcomes](https://stabiopharma.com/specialised-therapeutics-to-collaborate-with-pharmacy-phusion-to-improve-patient-outcomes/) - Singapore, 2 November 2018: Independent pharmaceutical company Specialised Therapeutics (ST) has struck a new agreement with specialty pharmacy services group Pharmacy Phusion to assist with the distribution and patient support for a new medicine that treats HER2 overexpressing early-stage breast cancer. Under the terms of the agreement, patients prescribed this new breast cancer treatment by
- [World-First Approval for Multiple Myeloma Drug Aplidin®](https://stabiopharma.com/world-first-approval-for-multiple-myeloma-drug-aplidin/) - Singapore, 11 December 2018: Australian multiple myeloma patients will have world-first access to a new first-in-class drug developed to treat the disease, following approval by Australian regulatory authorities. The drug, APLIDIN (plitidepsin) will be available to patients who have failed or are resistant to other therapies, after the Therapeutic Goods Administration (TGA) decision to approve APLIDIN
- [New Early Breast Cancer Drug to Be Made Available in Singapore via Special Access Program](https://stabiopharma.com/new-early-breast-cancer-drug-to-be-made-available-in-singapore-via-special-access-program/) - Singapore, 18 February 2019: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore from today via a Special Access Program. The drug, NERLYNX (neratinib) is an oral medication taken by women with HER2+ breast cancer who have completed adjuvant trastuzumab-based therapy. NERLYNX has been shown
- [New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Approved for Australian Women](https://stabiopharma.com/new-early-breast-cancer-drug-to-reduce-risk-of-recurrence-or-death-approved-for-australian-women/) - 19 March 2019: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer has today been approved for use in Australian patients. The drug, NERLYNX (neratinib) is an oral medication taken for 12 months by women with early stage HER2-positive (HER2+) breast cancer. It is
- [New Drug for Diabetes-Induced Vision Loss TGA-Approved for Australian patients](https://stabiopharma.com/new-drug-for-diabetes-induced-vision-loss-tga-approved-for-australian-patients/) - Melbourne, Australia and Atlanta, Georgia, 5 August 2019: Australian patients with diabetes-induced eye disease can now access a new treatment option that provides consistent and continuous treatment with long-lasting effect. The Therapeutic Goods Administration has now approved the drug ILUVIEN® (fluocinolone acetonide intravitreal implant), which delivers fluocinolone acetonide via a sustained release implant and provides therapeutic effect
- [ABRAXANE® Granted Orphan Drug Status for Pancreatic Cancer by Therapeutic Goods Administration](https://stabiopharma.com/abraxane-granted-orphan-drug-status-for-pancreatic-cancer-by-therapeutic-goods-administration/) - Melbourne, February 2010: A leading Australian breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been granted orphan drug status by the Therapeutic Goods Administration (TGA) for pancreatic cancer.
- [ABRAXANE® Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer](https://stabiopharma.com/abraxane-meets-primary-endpoint-in-phase-3-trial-for-advanced-non-small-cell-lung-cancer/) - LOS ANGELES and MELBOURNE – March 18, 2010: An international lung cancer trial has shown positive results in those patients treated with the leading breast cancer drug ABRAXANE in combination with carboplatin.
- [Study Shows Leading Breast Cancer Drug ABRAXANE® Increases Survival Time for Advanced Pancreatic Cancer](https://stabiopharma.com/study-shows-leading-breast-cancer-drug-abraxane-increases-survival-time-for-advanced-pancreatic-cancer/) - MELBOURNE, May, 2010: An international study of world-leading breast cancer drug ABRAXANE ® (nanoparticle albumin-bound paclitaxel) has shown promising results for patients with advanced pancreatic cancer when used in combination with Gemcitabine.
- [Celgene Acquires Abraxis BioScience and Leading Anti-Cancer Drug Abraxane](https://stabiopharma.com/celgene-acquires-abraxis-bioscience-and-leading-anti-cancer-drug-abraxane/) - Melbourne 20 October 2010: Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. The transaction adds Abraxane®(nanoparticle albumin-bound paclitaxel) to the company’s existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.
- [World Leading Breast Cancer Drug Now Available in New Zealand](https://stabiopharma.com/world-leading-breast-cancer-drug-now-available-in-new-zealand/) - Melbourne, Australia and Auckland, New Zealand – 21 February 2011 – New Zealand women now have access to a leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy. The drug, ABRAXANE, uses novel nanoparticle technology to deliver the chemotherapeutic agent to the tumour site and
- [Your Money and Breast Cancer](https://stabiopharma.com/your-money-and-breast-cancer/) -  The following article features in Issue One of the ST BREAST magazine. Vanessa was 43 years old and a single mum to two children aged five and three when she was diagnosed with breast cancer in 2016. She had a mortgage and took eight months off work, using all her accrued annual leave and sick
- [Lung Cancer Awareness Month: Brian's Story](https://stabiopharma.com/lung-cancer-awareness-month-brians-story/) - 73 year-old Brian Flynn loves a beer, his family and the St Kilda Football Club. The former industrial cleaner was close to retirement when first diagnosed with lung cancer five years ago. He had been a heavy smoker as a younger man, and was originally diagnosed after doctors investigated the source of his chest pain.
- [Small Cell Lung Cancer: Fraser’s Story](https://stabiopharma.com/small-cell-lung-cancer-frasers-story/) - LIVING WITH SMALL CELL LUNG CANCER: MEET FRASER STEWART New lung cancer therapies bring hope to people like Fraser Stewart. The 64-year-old father of two and retired diesel mechanic was diagnosed with Small Cell Lung Cancer in July 2019. Already he has endured rounds of chemotherapy, radiotherapy and immunotherapy. Now he hopes another
- [Suzanne Lombardo - International Women’s Day](https://stabiopharma.com/suzanne-lombardo-international-womens-day-monday-8-march/) - This International Women’s Day, we celebrate all women – particularly those who are facing a breast cancer diagnosis as well as those striving to make a difference. STA oncology liaison Suzanne Lombardo understands both perspectives. In this piece, she explains how her own experience with the disease has changed the way she now approaches her
- [Meet the Specialist: Dr Aminudin Rahman Bin Mohd Mydin](https://stabiopharma.com/meet-the-specialist-dr-aminudin-rahman-bin-mohd-mydin/) - Malaysian sarcoma specialist Dr Aminudin Rahman Bin Mohd Mydin, believes novel immunotherapy agents may one day change outcomes for difficult to treat sarcomas, with “promising responses” recorded in some of his own patients.
- [Oncotype DX<sup>®</sup>- Maxine Gladwin's Experience](https://stabiopharma.com/oncotype-dx-maxine-gladwins-experience/) - Maxine Gladwin was 47 and a single mum to three teenage daughters when she was diagnosed with breast cancer. When her oncologist advised chemotherapy treatment, she was devastated – fearing it would impact her health, her job and her ability to provide for her family. With support from her family, a sample of Maxine’s tumour
- [PBS Change for Leading Breast Cancer Drug ABRAXANE®](https://stabiopharma.com/pbs-change-for-leading-breast-cancer-drug-abraxane/) - Melbourne, 7 June 2010: Melbourne pharmaceutical company Specialised Therapeutics Australia (STA) wishes to announce a change in the Pharmaceutical Benefits Scheme (PBS) listing for its lead product ABRAXANE® (nanoparticle albumin-bound paclitaxel).
- [Updated Pancreatic Cancer Data Presented at International Cancer Conference](https://stabiopharma.com/updated-pancreatic-cancer-data-presented-at-international-cancer-conference/) - Melbourne, January 2014 - A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1 The updated OS data from the pivotal Phase III Metastatic Pancreatic Adenocarcinoma
- [Shelli's Story: How Breast Cancer Inspired 'Kit for Cancer'](https://stabiopharma.com/shellis-story-how-breast-cancer-inspired-kit-for-cancer/) - Two and a half years ago, Melbourne based high flyer Shelli Whitehurst was diagnosed with Stage 4 breast cancer. The devastating diagnosis inspired her to found a business that’s now helping other cancer patients around the world. Shelli Whitehurst was at the pinnacle of her career, enjoying the success of the marketing business she founded
- [First Australian Patients Treated with New Brain Tumour Drug - Gliolan®](https://stabiopharma.com/first-australian-patients-treated-with-new-brain-tumour-drug-gliolan/) - Melbourne, Australia: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas - brain tumours which typically have a poor prognosis. Neurosurgeons at Brisbane’s Wesley Hospital and the Royal Melbourne Hospital have pioneered the use of Gliolan® (5-aminolevulinic acid), describing it
- [Sports Broadcaster Takes on New Sporting Challenge](https://stabiopharma.com/sports-broadcaster-takes-on-new-sporting-challenge/) - Specialised Therapeutics Australia (STA) has a particular interest in pancreatic cancer and is committed to supporting efforts to advance understanding and improve clinical outcomes in this disease. Testimony to this commitment, we recently sponsored well-known television personality and sports broadcaster Tiffany Cherry to participate in the GI Cancer Institute’s ‘Gutsy Challenge’ - a seven day
- [ST Supporting Private Cancer Physicians of Australia](https://stabiopharma.com/st-supporting-private-cancer-physicians-of-australia/) - Meet Joel Wight - PCPA Profile Final year advanced trainee Joel Wight had his heart set on a surgical career, but as his medical training progressed, he realised this was not a long term passion. A “fortuitous” haematology rotation placement finally provided what he was looking for – cutting edge medicine with a strong focus
- [Teresa Hammer is Living with Triple Negative Breast Cancer](https://stabiopharma.com/teresa-hammer-is-living-with-triple-negative-breast-cancer/) - Teresa Hammer was 48 years old, recently re-married and “the happiest I had ever been” when she was diagnosed with triple-negative breast cancer almost three years ago. Despite her devastating diagnosis, she has tried to remain positive. She is now in remission and continues to work, as well as babysit her 8 month old grandson,
- [Endometrial Cancer Trial: Clinical Phase Completed](https://stabiopharma.com/endometrial-cancer-trial-clinical-phase-completed/) - Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017 CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced the occurrence of the 384th death in the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with Zoptrex™ (zoptarelin
- [ST Supporting Private Cancer Physicians of Australia](https://stabiopharma.com/st-supporting-private-cancer-physicians-of-australia-2/) - DR HILDA HIGH – PRIVATE CANCER GENETICIST. While Dr Hilda High was always intent on a career in medicine, her professional life took a few tangents before her true calling again beckoned. Following a dietetics degree and experience in computer programming, Hilda began her medical training relatively late in life, at age 32. Now, at
- [Under the Sea](https://stabiopharma.com/under-the-sea/) - Specialised Therapeutics’ Spanish partner PharmaMar employs a team of dedicated professional divers who are seeking new solutions for cancer, hundreds of metres below the sea’s surface. We are working closely with our esteemed international partner and have acquired exclusive rights to two cancer compounds of marine origin that are now in late stage development. These
- [Our Philanthropic Heart: ST and the Melbourne Coastrek](https://stabiopharma.com/our-philanthropic-heart-st-and-the-melbourne-coastrek/) - We are so proud of our intrepid ST foot soldiers, who last week took on the annual Melbourne Coastrek challenge and walked 30 kilometres in the name of charity. Two teams of ST walkers joined forces to trek along the rugged and spectacular Victorian coastline – a journey that took around 7 hours, large quantities
- [Living with Pancreatic Cancer](https://stabiopharma.com/living-with-pancreatic-cancer/) - Linda Wilson is an Australian mother, wife, grandmother and nurse who was diagnosed with pancreatic cancer five years ago. She had surgery, but was devastated when her cancer recurred. While she was given just months to live, she has steadfastly refused to abandon hope. She says, "I don't consider I am dying from pancreatic cancer,
- [Will I Require Chemotherapy?](https://stabiopharma.com/will-i-require-chemotherapy/) - Wendy Dunstone was diagnosed with early breast cancer and chose to have her tumour tested using the genomic test, Oncotype DX to guide decisions on her treatment. 59 year old Wendy was preparing to embark on the ‘trip of a lifetime’ when a routine breast screening revealed a hidden tumour. “I was feeling the healthiest
- [Access Program Initiated](https://stabiopharma.com/access-program-initiated/) - SARAH-JANE TASKER | THE AUSTRALIAN| 5 APRIL, 2018 New Breast Cancer Drug Reduces Risk of Relapse Australians with breast cancer can apply to receive a drug that reduces the risk of cancer returning, under a special access program. Nerlynx is targeted for use in women with HER 2+ early breast cancer. One in four women
- [ST's Business Development Team at #BIO2018](https://stabiopharma.com/sts-business-development-team-at-bio2018/) - Specialised Therapeutics delegates will attend the BIO International Convention, which returns to Boston Massachusetts this June. Hosted by the Biotechnology Innovation Organization (BIO), the event is designed to foster global biotechnology innovation by uniting the pharma industry with biotechnology companies, academic institutions, state biotechnology centres and related organisations. As in previous years, Specialised Therapeutics' Business
- [Senate Inquiry Into Rare Cancer Survival](https://stabiopharma.com/senate-inquiry-into-rare-cancer-survival/) - Senate Inquiry Into Rare Cancer Survival June, 2017: A Senate Committee was appointed earlier this year, to examine why some cancers still have low survival rates. The Senate Select Committee into Funding for Cancers with Low Survival was established following concerns that there had been little to no improvement in the survival rates for some
- [TAILORx Explained](https://stabiopharma.com/tailorx-explained/) - New findings from the landmark TAILORx study have revealed that the Oncotype DX Breast Cancer Assay is able to accurately identify the 70% of early breast cancer patients who can safely avoid chemotherapy, as well as the 30% of women for whom chemotherapy is optimal. This investigation was the largest adjuvant breast cancer treatment trial
- [Living with Multiple Myeloma: A Patient’s Story](https://stabiopharma.com/living-with-multiple-myeloma-a-patients-story/) - Dot and Terry Arnold were teenage sweethearts who drifted apart but found themselves happily reunited in later life. Both had been married, but Terry was divorced and Dot had been widowed. On Terry’s retirement, they dreamed of travelling Australia in their “old caravan with new curtains”, even managing a few short trips to South Australia,
- [International Women's Day](https://stabiopharma.com/international-womens-day/) - March 8 is International Women's Day. Today, we recognise the clinicians, patients and our colleagues whose stories always inspire us to be better at work, and in life. We know everyone has a story. These three women have generously shared some of the diverse experiences that have shaped their lives and careers. Kate’s Story
- [Mother's Day](https://stabiopharma.com/mothers-day/) - On Mother’s Day 2019 we recognise the Mothers and Daughters who face a breast cancer diagnosis together. Janet and Julie Kesby have both been diagnosed twice and have supported each other all the way. Both are well at the moment and say their bond was always good; now it’s unbreakable. They shared their stories
- [Logistics: How ST Transports Specialty Medicines](https://stabiopharma.com/logistics-how-st-transports-specialty-medicines/) - Specialised Therapeutics ensures its specialty medicines are transported seamlessly and reliably. Sophisticated planning makes this happen. Our Quality Assurance Manager and GxP Associate David Wilson explains below. OUR CAPABILITY: Specialised Therapeutics’ Quality Assurance Manager David Wilson explains how we transport specialist medicines to patients around the world What are the main considerations ST
- [Philanthropy: MZFF recognised at TLC Ambulance Launch](https://stabiopharma.com/philanthropy-mzff-recognised-at-tlc-ambulance-launch/) - The MZFF is extremely proud to be a foundation sponsor of the TLC Ambulance Project - an initiative developed by TLC for Kids in collaboration with Ambulance Victoria. This project will enable terminally ill children to be transported to a final destination of their choice - under the care of a full volunteer ambulance crew.
- [ST COVID-19 Update](https://stabiopharma.com/st-covid-19-update/) - Like all companies globally, ST is closely monitoring the COVID-19 pandemic. In any kind of health crisis, all pharmaceutical companies must contribute their expertise to find answers. A key ST partner is Spanish company PharmaMar, which has announced its novel marine-derived multiple myeloma compound is showing encouraging laboratory results as a promising COVID-19 target. ST
- [Brain Tumour Awareness Month 2020: Prof Kate Drummond](https://stabiopharma.com/brain-tumour-awareness-month-2020-prof-kate-drummond/) - Neurosurgeon Professor Kate Drummond says all brain cancer patients want more time. “There is always a wedding, a baby, an event or someone that needs to be cared for,” she says. But with the most serious form of brain cancer, glioblastoma multiforme or GBM, time runs out too quickly - despite the greatest efforts of
- [Breast Friends & Modern Surgery](https://stabiopharma.com/breast-friends-modern-surgery/) - The following article features in Issue One of the ST BREAST magazine. Within 72 hours of her breast cancer diagnosis four years ago, Ally Fairbairn found herself in the offices of Melbourne breast cancer surgeon Chantel Thornton. She was pragmatic, telling the surgeon to just “do whatever you have to do and tell me
- [Minds Matter](https://stabiopharma.com/minds-matter/) - The following article features in Issue One of the ST BREAST magazine. Dr Lisa Beatty is a Senior Clinical Psychologist and Cancer Council South Australia Senior Research Fellow at the Flinders Centre for Innovation in Cancer. She has expertise in psycho-oncology - the scientific exploration of the psychological impact and treatment of cancer. BETWEEN
- [Sarcoma Awareness Month: Dr Susie Bae](https://stabiopharma.com/sarcoma-awareness-month-dr-susie-bae/) - Many patients are “scared of being a guinea pig” but the reality is that they’re likely to have better outcomes if they choose to take part in a clinical trial. So says Dr Susie Bae, who specialises in both sarcoma and breast cancers. Her advice to patients is always to participate in a trial if
- [Sarcoma Awareness Month: A/Prof Jayesh Desai](https://stabiopharma.com/sarcoma-awareness-month-a-prof-jayesh-desai/) - Australians who are diagnosed with sarcoma have around a 70% chance of complete cure if they are diagnosed early, according to one of the country’s leading sarcoma experts. Associate Professor Jayesh Desai says making a correct diagnosis at early stage - before the cancer has spread to other organs - is crucial to helping patients
- [ST named as PRIME Awards finalist](https://stabiopharma.com/st-named-as-prime-awards-finalist/) - At ST, we pride ourselves on customer service. We deal with healthcare professionals every day to discuss our portfolio of specialist therapies and the patients who might benefit, and we never forget that there is a person and a family at the heart of every discussion.
- [STA Named Employer of Choice in 2020 ABA Business Awards](https://stabiopharma.com/sta-named-employer-of-choice-in-2020-aba-business-awards/) - Melbourne, Australia, 8 October 2020: Independent pharmaceutical company Specialised Therapeutics Australia (STA) has been recognised as an Employer of Choice in The Australian Business Awards 2020. The prestigious awards recognize organisations demonstrating business innovation, product innovation, technological achievement and employee engagement via a set of comprehensive award categories. The Employer of Choice (EOC) accolade in
- [Storytelling for Business](https://stabiopharma.com/storytelling-for-business/) - Wellbeing newsletter prompts "outstanding" employee response A strong focus on wellbeing has provided a safe space for employees to share personal stories at Specialised Therapeutics Australia (STA), which has today been named an employer of choice in the Australian Business Awards. STA launched a light-hearted, monthly wellbeing newsletter prior to COVID-19, but made it
- [An Early Breast Cancer Diagnosis](https://stabiopharma.com/an-early-breast-cancer-diagnosis/) - The following article features in Issue One of the ST BREAST magazine. Heather Plaister clearly remembers the moment she found a breast lump. A woman of great faith, she had said a morning prayer before asking God if there was someone she should be praying for. “Then it was just like a thought process
- [Our Philanthropic Heart](https://stabiopharma.com/our-philanthropic-heart/) - ST is a long-standing sponsor and supporter of Specialists Without Borders (soon to become Pangea). This not-for-profit group was established in 2008 and its mission is to send teams of Australian medical specialists to developing countries where they can upskill their peers in innovative and potentially life-saving medical techniques. Our CEO Carlo Montagner joined
- [10 Years of Meeting Unmet Needs](https://stabiopharma.com/10-years-of-meeting-unmet-needs/) - ST was founded with a mission of meeting unmet medical needs. In line with this ethos, we are passionate about helping all patients access new and innovative medicines that can change lives. In the past decade, we have worked closely with Rare Cancers Australia to ensure that new, innovative and potentially life-changing therapies are available
- [Pharma in Focus: 10 February, 2022](https://stabiopharma.com/pharma-in-focus-10-february-2022/) - PHARMA IN FOCUS By Christine Spiteri 10 February 2022 Who's Mandated a Third Jab? Specialised Therapeutics has made a third COVID-19 vaccine compulsory for all staff, to ensure a safe office environment for employees returning to work. The team was told on Christmas Eve last year that booster shots for those who were eligible would
- [World Cancer Day 2022](https://stabiopharma.com/world-cancer-day-2022/) - Rare Cancers Australia CEO Richard Vines discusses affordable access to specialist medicines. Click for more.
- [Skylark – WA oncologist Dr Andrew Dean shares his passion for aviation](https://stabiopharma.com/skylark-wa-oncologist-andrew-dean-shares-his-passion-for-aviation/) - As a young boy, Andrew Dean was fascinated with aeroplanes. But the son of Liverpool publicans quickly realised that flying lessons were a lofty pursuit his family probably could not afford. It was many years later, after training first as a palliative care and internal medicine physician that the medical oncologist decided his sky-high ambition was finally within reach.
- [10 Years of Giving](https://stabiopharma.com/10-years-of-giving-3/) - ST is committed to providing and leaving an enduring legacy, not only in Australia but overseas. Sustainable healthcare and education are among our philanthropic passions. We were intrigued when we first heard about the work of Specialists Without Borders (now Pangea). This not-for-profit group, founded in 2008, ensures large contingents of Australian medical professionals are
- [10 Years of Innovation](https://stabiopharma.com/10-years-of-innovation/) - ST prides itself on being innovative and entrepreneurial. We set a new pharma industry benchmark in Australia when we decided to stop bonus payments to our in-field representatives based on sales volumes in their territories. We wanted them to focus on their customers, build real relationships and educate, rather than sell. We think it’s worked.
- [10 Years of Compassion](https://stabiopharma.com/10-years-of-compassion/) - Linda Wilson is an Australian mother, wife, grandmother and nurse who was diagnosed with pancreatic cancer five years ago. She had surgery, but was devastated when her cancer recurred. While she was given just months to live, she has steadfastly refused to abandon hope. She says, "I don't consider I am dying from pancreatic cancer,
- [10 Years of Giving](https://stabiopharma.com/10-years-of-giving-2/) - Being philanthropic is important to us and STA has a long history of giving. In the past 10 years, we have donated more than $21 million worth of medicine to patients on compassionate grounds and delivered more than $3.5 million to research and development. But one of our greatest achievements has been the establishment of
- [10 Years of Giving](https://stabiopharma.com/10-years-of-giving/) - It was three years ago that our family decided we wanted to give and support causes beyond our local community. After making this decision, we were made aware of the struggles facing the people of Timor-Leste. While this region is geographically close to Australia – it’s faster to travel by plane from Darwin to Dili
- [Abraxis Bioscience and Specialised Therapeutics Announce Approval to Market ABRAXANE® for Metastatic Breast Cancer in New Zealand](https://stabiopharma.com/abraxis-bioscience-and-specialised-therapeutics-announce-approval-to-market-abraxane-for-metastatic-breast-cancer-in-new-zealand/) - Los Angeles, Calif. and Melbourne Australia – July, 2010 – Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline
- [Specialised Therapeutics and Helsinn Group Announce a PBS Listing for ALOXI® (Palonosetron) in Australia](https://stabiopharma.com/specialised-therapeutics-and-helsinn-group-announce-a-pbs-listing-for-aloxi-palonosetron-in-australia/) - Melbourne, Australia and Lugano, Switzerland 1st November 2010: A world leading anti-nausea/anti-vomiting drug for cancer patients undergoing chemotherapy will be available in Australia on the Pharmaceutical Benefits Scheme (PBS) from November 1st 2010. Aloxi® (palonosetron hydrochloride) is a new therapy to prevent acute and delayed nausea and vomiting which can occur in cancer patients undergoing chemotherapy1. The
- [Specialised Therapeutics to License Brain Tumour Visualisation Drug GLIOLAN® in Australia & NZ](https://stabiopharma.com/specialised-therapeutics-to-license-brain-tumour-visualisation-drug-gliolan-in-australia-nz/) - Melbourne, Australia and Hamburg, Germany, 17 June 2011: A new drug which aids neurosurgeons to better visualise and operate on high grade glioma, a type of brain tumour which has a poor prognosis, has been in-licensed by Melbourne bio-pharmaceutical company Specialised Therapeutics Australia Pty Ltd (STA). STA has signed a binding term sheet with German company
- [STA Receives TGA Approval for ABRAXANE® in Combination with Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer](https://stabiopharma.com/sta-receives-tga-approval-for-abraxane-in-combination-with-gemcitabine-for-first-line-treatment-of-metastatic-pancreatic-cancer/) - Melbourne, Australia - March, 2014: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved indication is: ABRAXANE, in combination with gemcitabine, is indicated for the first-line
- [STA Announces Breakthrough Cancer Drug ABRAXANE® to be PBS Listed for Metastatic Pancreatic Cancer](https://stabiopharma.com/sta-announces-breakthrough-cancer-drug-abraxane-to-be-pbs-listed-for-metastatic-pancreatic-cancer/) - Melbourne, Australia, 31 October 2014: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce ABRAXANE®(nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be reimbursed via the Pharmaceutical Benefits Scheme (PBS) for patients with metastatic pancreatic cancer from the 1st of November. In Australia, pancreatic cancer is the 5th most common cause of cancer mortality. Pancreatic cancer
- [Ariad and STA Announce Approval of ICLUSIG™ (ponatinib) in Australia](https://stabiopharma.com/ariad-and-sta-announce-approval-of-iclusig-ponatinib-in-australia/) - Cambridge, MA, and Melbourne, Australia, November 24, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of ICLUSIG™ (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). The Australian Product Information for ICLUSIG states that it is indicated for the treatment of adult patients with: Chronic
- [TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)](https://stabiopharma.com/tga-approves-akynzeo-netupitant-palonosetron-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv/) - Melbourne, Australia, and Lugano, Switzerland, 8 May 2015: Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration (TGA) has approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.
- [10 Years of Giving: Our Commitment to Global Health](https://stabiopharma.com/10-years-of-giving-our-commitment-to-global-health/) - Specialised Therapeutics is proud and committed to supporting a range of organisations and charities that are aligned with our business and healthcare mission. This philosophy and mindset is embedded in all parts of our business. Since we were founded 11 years ago, we have prudently selected synergistic causes where our contribution can make a difference
- [ST and World Vision](https://stabiopharma.com/st-and-world-vision/) - Celebrating Christmas together is a part of working life at Specialised Therapeutics. We traditionally share a lovely meal, entertainment and gifts, but we are always mindful of those who are less fortunate during the festive season. Each year, ST founders Carlo Montagner and Bozena Zembrzuski make a donation to World Vision on behalf of every
- [Inspire: Living Life with Breast Cancer August 2017](https://stabiopharma.com/inspire-living-life-with-breast-cancer-august-2017/) - See below Specialised Therapeutics' inaugural edition of Inspire, a magazine for women living with breast cancer. To view this publication, move your mouse over the image below and click on the Click to read button.
- [New PBS Listing for Leukaemia Drug ICLUSIG™ (ponatinib)](https://stabiopharma.com/new-pbs-listing-for-leukaemia-drug-iclusig-ponatinib/) - Singapore, September 1, 2018: A DRUG currently used to treat Chronic Myeloid Leukaemia (CML) will be available on the Pharmaceutical Benefits Scheme from today as a new treatment for another aggressive form of the disease. The drug, ICLUSIG (ponatinib) will now be available to all Philadelphia-positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients, who are intolerant
- [Specialised Therapeutics Asia Unveils ‘Track and Trace’ Pharma Model to Boost Drug Security, Improve Patient Safety](https://stabiopharma.com/specialised-therapeutics-asia-unveils-track-and-trace-pharma-model-to-boost-drug-security-improve-patient-safety/) - Singapore, 17 May 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) is launching an innovative tracking system that will enable real time monitoring of every unit of drug product provided through its supply chain – from packing to patient. The company, which markets specialist medicines to patients in Australia, New Zealand and across South East Asia,
- [New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority](https://stabiopharma.com/new-early-breast-cancer-drug-approved-by-singapore-health-sciences-authority/) - Singapore, 3 December, 2019: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence has received approval in Singapore – at least six months ahead of its expected schedule. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based
- [New Early Breast Cancer Drug Available Now in Singapore](https://stabiopharma.com/new-early-breast-cancer-drug-available-now-in-singapore/) - Singapore, 23 April 2020: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now commercially available to Singapore patients. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy. It has been shown to significantly reduce
- [New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis](https://stabiopharma.com/new-small-cell-lung-cancer-drug-accepted-for-tga-evaluation-under-project-orbis/) - Singapore and Melbourne, Australia, 3 June 2020: A NOVEL marine-derived drug to treat Small Cell Lung Cancer (SCLC) has been granted a provisional designation by the Therapeutic Goods Administration (TGA), based on encouraging results from an international trial evaluating its safety and efficacy in several solid tumours, including SCLC. Data from a key Phase 2
- [New Early Breast Cancer Drug Now Approved in Malaysia](https://stabiopharma.com/new-early-breast-cancer-drug-now-approved-in-malaysia/) - Singapore, 17 July 2020: A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy. It has been shown to significantly reduce
- [STA Named Employer of Choice in 2020 ABA Business Awards](https://stabiopharma.com/sta-named-employer-of-choice-in-2020-aba-business-awards-2/) - Melbourne, Australia, 8 October 2020: Independent pharmaceutical company Specialised Therapeutics Australia (STA) has been recognised as an Employer of Choice in The Australian Business Awards 2020. The prestigious awards recognize organisations demonstrating business innovation, product innovation, technological achievement and employee engagement via a set of comprehensive award categories. The Employer of Choice (EOC) accolade in particular,
- [Breast Cancer Patients Can Access New Interest-Free Payment Plan for Genomic Test That May Help Them Avoid Chemotherapy](https://stabiopharma.com/breast-cancer-patients-can-access-new-interest-free-payment-plan-for-genomic-test-that-may-help-them-avoid-chemotherapy/) - Melbourne, Australia, 15 March 2021: BREAST cancer patients who wish to have a genomic test that may help them to avoid chemotherapy can now take out interest-free payment plans of up to two years to pay for the test, following an exclusive arrangement between independent pharmaceutical company Specialised Therapeutics Australia (STA) and Latitude Finance.
- [Specialised Therapeutics Asia to Re-introduce Global Sarcoma Drug to Patients in Singapore, Malaysia and Brunei](https://stabiopharma.com/stasia-reintroduce-global-sarcoma-drug/) - Singapore, 9 September 2021: A globally regarded sarcoma therapy that has been shown to improve progression free survival1 is now being re-introduced in key regions of South-East Asia by independent pharmaceutical company Specialised Therapeutics Asia (STA). The compound YONDELIS® (trabectedin) will be available to advanced sarcoma patients via their treating oncologists in Singapore, Malaysia and
- [New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients](https://stabiopharma.com/new-therapy-treat-advanced-small-cell-lung-cancer/) - Singapore, 14 September 2021: AUSTRALIAN patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new therapy that may improve outcomes. The therapy, ZEPZELCA™ (lurbinectedin) has been approved by the Therapeutic Goods Administration (TGA) “for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed
- [New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA<sup>®</sup> (lurbinectedin) Approved in Singapore](https://stabiopharma.com/new-therapy-to-treat-advanced-small-cell-lung-cancer-zepzelca-lurbinectedin-approved-in-singapore/) - Singapore, 22 September 2021: SINGAPORE patients with an aggressive form of lung cancer (metastatic small cell cung cancer) can now access a new therapy that may improve outcomes. The drug ZEPZELCA (lurbinectedin) has been provisionally approved by Singapore’s Health Sciences Authority (HSA) “for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who
- [Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery](https://stabiopharma.com/royal-melbourne-hospital-first-public-hospital-in-australia-to-adopt-new-technology-for-brain-tumour-surgery/) - Melbourne, Australia May 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital. In 2011, The Royal Melbourne Hospital trialled the drug with great success, and is expected to treat up to an additional 25
- [ABRAXANE® in Focus at International Conference](https://stabiopharma.com/abraxane-in-focus-at-international-conference/) - CANCER DRUG ABRAXANE® IN FOCUS AT INTERNATIONAL CONFERENCE Delegates to hear trial results for future possible ABRAXANE indications including lung cancer and melanoma Melbourne: 27 May 2010: World leading advanced breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) will be in focus at a leading international medical conference in Chicago next week. Specialised Therapeutics Australia Pty Ltd (STA), which
- [ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study](https://stabiopharma.com/abraxane-meets-primary-endpoint-of-overall-survival-improvement-in-phase-iii-advanced-pancreatic-cancer-study/) - Melbourne, November 2012 Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. This is now the fourth disease in which ABRAXANE has demonstrated positive phase III results,
- [Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation](https://stabiopharma.com/melbourne-biopharmaceutical-company-named-first-corporate-sponsor-of-international-medical-aid-organisation/) - Melbourne, June 2013 Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries. The company has become the inaugural donor for the Specialists Without Borders (SWB) organisation, an Australian based non-profit entity established in
- [ICLUSIG™ to be PBS Listed November 1, 2015](https://stabiopharma.com/iclusig-to-be-pbs-listed-november-1-2015/) - ICLUSIG will be listed for the treatment of the following patients: Chronic Myeloid Leukaemia (CML) patients who are resistant or intolerant to both nilotinib and dasatinib CML patients who are expressing the T315I mutation after prior TKI therapy Philadelphia positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients who are expressing the T315I mutation after prior therapy
- [Call to Screen Type 2 Diabetics for Pancreatic Cancer](https://stabiopharma.com/call-to-screen-type-2-diabetics-for-pancreatic-cancer/) - “I think the biggest revolutions in pancreas cancer treatment are yet to come.” Dr Lorraine Chantrill has been a medical oncologist for 10 years, with a particular focus on pancreatic cancer “because it is so terrible and there is so much room for improvement”. She notes that average survival rates for pancreas cancer have improved
- [Keryn Barnett is Living with Triple Negative Breast Cancer](https://stabiopharma.com/keryn-barnett-is-living-with-triple-negative-breast-cancer/) - TELL US ABOUT YOU AND WHEN YOU WERE DIAGNOSED. I am 45 years old, I have two girls and I am a single mother. I was diagnosed with triple-negative breast cancer at the end of 2014. It was right on Christmas – the worst Christmas ever. My 12 year-old was just bawling her eyes out,
- [Corporate Support: ST Supports the GI Cancer Institute](https://stabiopharma.com/corporate-support-st-supports-the-gi-cancer-institute/) - ST is a longstanding supporter of the GI Cancer Institute, which saves lives by funding important research into gastro-intestinal cancers, including pancreatic cancer. In a few days, medical oncologist Dr Lorraine Chantrill will walk the Larapinta Trail in the Northern Territory to raise new funds. In this short video, she explains her mission and motivation.
- [Our Philanthropic Heart: A Hall without Walls](https://stabiopharma.com/our-philanthropic-heart-a-hall-without-walls/) - Our Philanthropic Heart: A Hall without Walls By Carlo Montagner and Bozena Zembrzuski It was three years ago that our family decided we wanted to give and support causes beyond our local community. After making this decision, we were made aware of the struggles facing the people of Timor-Leste. While this region is geographically
- [Federal Treasurer Josh Frydenberg Opens New ST Headquarters](https://stabiopharma.com/federal-treasurer-josh-frydenberg-opens-new-st-headquarters/) - August 2018: Australia’s new Federal Treasurer Josh Frydenberg officially unveiled ST’s new Melbourne headquarters, an event coinciding with the company’s 10 year anniversary. The deputy Liberal Party leader joined staff and other local dignitaries at the celebration, praising ST’s commitment to innovation and recognising it’s contribution to Australian healthcare.
- [World First: AU Patients First to Access Drug Developed from Sea Squirt](https://stabiopharma.com/world-first-au-patients-first-to-access-drug-developed-from-sea-squirt/) - The following news clip appeared on National Nine News. Click on the thumbnail to view.
- [ST wins Prime Healthcare Award](https://stabiopharma.com/st-wins-prime-healthcare-award/) - We are so proud, that in an exceptional field of finalists (including some or the world's biggest pharma companies) it was our breast cancer patient support program that took out top prize. Special thanks to our program collaborators Pharmacy Phusion for their support and assistance overseeing this tremendous effort.
- [RxPONDER: Medical Oncologist Dr Richard de Boer](https://stabiopharma.com/rxponder-medical-oncologist-dr-richard-de-boer/) - Medical oncologist Dr Richard de Boer discusses interim results from the Oncotype DX RxPONDER study, presented at the 2020 San Antonio Breast Cancer Symposium. Click on the video banner above to watch the video.
- [Living with GIST - Sarah McGoram's Story](https://stabiopharma.com/living-with-gist-sarah-mcgorams-story/) - Canberra mother, wife and school teacher Sarah McGoram was diagnosed with GIST 25 years ago - and given just a year to live. She has defied all odds and now gives hope to other Australians living with the disease. Click on the video above to hear her story.
- [Medical Oncologist Professor John Zalcberg explains gastrointestinal stromal tumours - GIST](https://stabiopharma.com/professor-john-zalcberg-what-is-gist/) - What is GIST? We are passionate about making a difference for patients living with rare cancers. Here, Professor John Zalcberg provides an overview of Gastrointestinal Stromal Tumours. Click for more.
- [Professor John Zalcberg reacts to the QINLOCK® (ripretinib) PBS listing](https://stabiopharma.com/professor-john-zalcberg-reacts-to-the-qinlock-ripretinib-pbs-listing/) - ST is delighted to announce that our therapy QINLOCK® (ripretinib) was reimbursed for eligible Australian GIST patients from December 1 2021. International GIST expert Professor John Zalcberg reacts to the listing. Click for more.
- [Pharma in Focus: 21 December, 2021](https://stabiopharma.com/pharma-in-focus-21-december-2021/) - PHARMA IN FOCUS By Christine Spiteri 21 December 2021 Job Boom Hits Growing Pharma Specialised Therapeutics is experiencing a mini-jobs boom, with the company's growing portfolio and expansion across South East Asia requiring a boost to its workforce. The company currently has a staff of about 40 but is actively looking to fill five new
- [Breast Cancer Awareness Month](https://stabiopharma.com/breast-cancer-awareness-month/) - Breast Cancer Awareness Month We know that on average, 1 in 8 Australian women will develop breast cancer. To acknowledge Breast Cancer Awareness Month, we share the story of Paula Beevor, who became the ‘one’ and decided to chase her dream of a new life in Australia. This is her story. To read full text,
- [Start Moving](https://stabiopharma.com/start-moving/) - Dale Ischia is an accredited exercise physiologist and a cancer exercise specialist. She says it’s now “beyond doubt” that exercise is vital before, during and after a breast cancer diagnosis, with the benefits not only physical.
- [BREAST Issue #1](https://stabiopharma.com/breast-issue-1/) - Introducing BREAST, a magazine produced by ST for breast cancer patients. Thanks to all patients, families and clinicians who provided their stories and insights. Click on the image below to view as a flipbook. We look forward to your feedback. 
- [Breast Cancer Myths](https://stabiopharma.com/breast-cancer-myths/) - 1. All breast cancer patients have the same type of treatment. Different patients respond differently to treatments, and the sequence and type of treatment should always be tailored to the individual. One person’s treatment plan and experience is very unlikely to be the same as that of a friend, relative or colleague. There are many
- [Brain Tumour Awareness Month 2020: Prof Antonio Di Ieva](https://stabiopharma.com/brain-tumour-awareness-month-2020-prof-antonio-di-ieva/) - Professor Antonio Di Ieva predicts and hopes that brain cancer will be a manageable chronic disease “much like diabetes” by 2030, and patients will have a vastly improved quality of life. Speaking to Specialised Therapeutics to mark Brain Tumour Awareness Month, the accomplished neurosurgeon, who has performed more than 2000 brain surgeries in the past
- [COVID-19](https://stabiopharma.com/covid-19/) - Specialised Therapeutics CEO Carlo Montagner has appeared on a national business program, discussing the potential impact of the COVID-19 crisis on the global pharma supply chain, and the race for an effective COVID-19 vaccine and therapy. He told business journalist Ahron Young that ST's Spanish partner PharmaMar is now fast-tracking trials of its myeloma compound
- [Introducing BREAST](https://stabiopharma.com/introducing-breast/) - Thousands of Australian women are affected by breast cancer every year. ST is committed to providing new therapies that can make a difference, but we also want to share the stories and experiences of those women who are diagnosed, as well as insights from some of Australia's most respected oncologists. We've produced a breast cancer
- [Managing your Diet](https://stabiopharma.com/managing-your-diet/) - The following article features in Issue One of the ST BREAST magazine. BEFORE, DURING AND AFTER BREAST CANCER Good nutrition can impact breast cancer treatment tolerance and recovery,1 as well as reduce the risk of recurrence1,2 and improve long-term health, according to Accredited Practising Dietitians (APDs) Lauren Atkins and Elise Den. The pair, who co-founded OnCore Nutrition
- [RxPONDER: Professor Arlene Chan](https://stabiopharma.com/rxponder-professor-arlene-chan/) - Professor Arlene Chan discusses interim results from the Oncotype DX RxPONDER study, presented at the 2020 San Antonio Breast Cancer Symposium. Click on the video banner above to watch the video.
- [Comment: Rare Cancers Australia CEO Richard Vines](https://stabiopharma.com/comment-rare-cancers-australia-ceo-richard-vines/) - Rare Cancers Australia CEO Richard Vines says Australian GIST patients were determined to help achieve a PBS listing for a new therapy to treat the disease and their persistence has paid off with QINLOCK® (ripretinib) now reimbursed. Click for more.
- [Renee's GIST Experience](https://stabiopharma.com/renees-gist-experience/) - Melbourne mother of two Renee Van Beelan was diagnosed with GIST (Gastrointestinal Stromal Tumours) almost five years ago. Her baby daughter was just eight weeks old and the devastated new mother did not know what the future held. New therapies provide hope for the future. Click on the video above to hear Renee speak about
- [STA Announces New US Partner](https://stabiopharma.com/sta-announces-new-us-partner/) - PHARMADISPATCH 6 November 2020 Australian Company Adds to its Oncology Portfolio with GIST Therapy November 6, 2020 -- Privately owned Australian pharmaceutical company Specialised Therapeutics Asia has signed an exclusive distribution agreement for a new therapy to treat advanced gastrointestinal stromal tumours (GIST). The agreement with US-based Deciphera Pharmaceuticals covers the commercialisation of switch-control
- [nzDoctor.co.nz: 1 May, 2017](https://stabiopharma.com/nzdoctor-co-nz-1-may-2017/) - nzDoctor.co.nz (Un-Doctored) 5 April 2017 Breakthrough brain tumour visualisation drug Gliolan to be listed on NZ hospital medicines list from 1 June Media release from Specialised Therapeutics Group GLIOLAN® to be funded in all NZ District Health Board (DHB) hospitals following PHARMAC reimbursement decision Listing follows application by leading NZ neurosurgeon GLIOLAN has
- [Herald Sun: 17 September, 2011](https://stabiopharma.com/herald-sun-17-september-2011/) - HERALD SUN (MELBOURNE) By Lucie van den Berg 17 September 2011 Olivia Has a Million Reasons to Smile Olivia Newton-John had one million reasons to be happy yesterday when a Melbourne family made an unprecedented donation to her cancer centre that opens in June.But their generosity reduced the singer to tears. "I'm so touched
- [Channel 7 News: November 2015](https://stabiopharma.com/channel-7-news-november-2015/) - The following story appeared on Channel 7 News nationally following a PBS listing. Click to view.
- [Channel 9 News: November 2015](https://stabiopharma.com/channel-9-news-november-2015/) - The following story appeared on Channel 9 News nationally following a PBS listing. Click to view.
- [Herald Sun: 8 April, 2016](https://stabiopharma.com/herald-sun-8-april-2016/) - HERALD SUN (MELBOURNE) By Carlo Montagner 8 April 2016 PBS Price Cuts Cruel Pharma Innovation Earlier this week, pharmaceutical companies across the country received a substantial financial penalty, as the federal government’s Pharmaceutical Benefits Scheme cost-saving agenda took effect. Under this plan, expected to save the government around $3.7 billion over the next five
- [Herald Sun: 5 November, 2016](https://stabiopharma.com/herald-sun-5-november-2016/) - HERALD SUN (MELBOURNE) By Grant McArthur 5 November 2016 Linda Defies Odds: Brave cancer survivor is determined to live life to the full FEW people would laugh about their superannuation running out while they still have a lot of living left to do. But for Linda Wilson, the prospect of outliving her nest egg
- [Herald Sun: 2 February, 2017](https://stabiopharma.com/herald-sun-2-february-2017/) - HERALD SUN (MELBOURNE) By Carlo Montagner 10 February 2017 When Customers Come First, Not Dangling Carrots I have just bought a red Tesla. It’s a battery operated, engineering marvel that doesn’t require petrol, can be recharged via a rooftop solar panel, is sleek, modern and chivalrous to boot - with doors that open
- [Waikato Times: 1 June, 2017](https://stabiopharma.com/waikato-times-1-june-2017/) - Waikato Times By Rachel Thomas 1 June 2017 Glowing Tumours Help Patients’ Odds It was by chance that Alice Chambers’ brain tumour was found. The 33-year-old was loading the boot of her jeep when the window slammed down on her head so hard ‘‘I thought someone had hit me with a baseball bat’’.
- [Southland Times: 1 June, 2017](https://stabiopharma.com/southland-times-1-june-2017/) - Southland Times By Rachel Thomas 1 June 2017 Glowing Tumours Help Patients’ Odds It was by chance that Alice Chambers’ brain tumour was found. The 33-year-old was loading the boot of her jeep when the window slammed down on her head so hard ‘‘I thought someone had hit me with a baseball bat’’. Days
- [The Australian: 25 July, 2017](https://stabiopharma.com/the-australian-25-july-2017/) - The Australian By Sarah-Jane Tasker 25 July 2017 New Push for Brain Cancer Drug Leading neurosurgeon Kate Drummond has called on the Turnbull government to break the “bureaucratic mould” and approve reimbursement of a drug that prolongs the life of Australian brain cancer patients. The debate on access to the drug was reignited
- [The Australian: 5 October, 2017](https://stabiopharma.com/the-australian-5-october-2017/) - The Australian By Sarah-Jane Tasker 5 October 2017 Patients Forced into Chemo: No Funds for Breast Cancer Testing Globally recognised technology that could spare thousands of Australian breast cancer patients from unnecessary chemotherapy will remain out of reach for many after the federal government refused to fund the expensive test. The test, which provides a
- [Herald Sun: 5 October, 2017](https://stabiopharma.com/herald-sun-5-october-2017/) - The Australian By Sue Dunlevy 5 October 2017 Test rebate rejected: Outrage over breast cancer ruling NO Medicare rebate will be offered for a breakthrough new test that could save thousands of breast cancer patients from debilitating chemotherapy. The $4500 test, which can also identify aggressive breast cancers that do need chemotherapy, is subsidised in
- [The Australian: 6 April, 2018](https://stabiopharma.com/the-australian-6-april-2018/) - The Australian By Sarah-Jane Tasker 6 April 2018 New Breast Cancer Drug Reduces Risk of Relapse Australians with breast cancer can apply to receive a drug that reduces the risk of cancer returning, under a special access program. Nerlynx is targeted for use in women with HER 2+ early breast cancer. One in four women
- [The Australian: 4 June, 2018](https://stabiopharma.com/the-australian-4-june-2018/) - The Australian 4 June 2018 Breast Cancer Patients Can Skip Chemo: Study CHICAGO: About 70 per cent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after their tumours have been removed, US researchers say. “This is a major finding,” said Larry Norton, a breast cancer expert
- [Channel 9: 4 June, 2018](https://stabiopharma.com/channel-9-4-june-2018/) - Channel 9 4 June 2018 Interview with Dr Penny Adams, Medical Expert Interview with Dr Penny Adams, Medical Expert. There is a medical breakthrough for women with the most common form of early-stage breast cancer, with new research revealing that genetic testing could help them skip chemotherapy without affecting their chances of beating the disease.
- [West Australian: 19 March, 2019](https://stabiopharma.com/west-australian-19-march-2019/) - The West Australian (Perth) 19 March 2019 Cancer Drug Nod A new breast cancer wonder drug has been approved for use in Australia from today. Women diagnosed with the aggressive HER2+ breast cancer have a one in four chance of relapse, even after surgery and chemotherapy. Nerlynx reduces the five-year risk of death or recurrence
- [Herald Sun: 19 March, 2019](https://stabiopharma.com/herald-sun-19-march-2019/) - HERALD SUN (MELBOURNE) By Aleks Devic 19 March 2019 Breast cancer hope: Regulator green-lights treatment A NEW breast cancer wonder drug has been approved for use in Australia from today. Women diagnosed with the aggressive HER2+ breast cancer have a one in four chance of relapse, even after surgery and chemotherapy. But test data has
- [3AW: 19 March, 2019](https://stabiopharma.com/3aw-19-march-2019/) - 3AW 19 March 2019 Interview with Dr Richard de Boer, Oncologist, Peter MacCallum Cancer Centre Interview with Dr Richard de Boer, oncologist, Peter MacCallum Cancer Centre. Mitchell says it has been discovered a drug is effective in reducing the chance of relapse of breast cancer. De Boer explains this drug has been approved by the
- [Australian Pharmacist: 1 May, 2019](https://stabiopharma.com/australian-pharmacist-1-may-2019/) - AUSTRALIAN PHARMACIST 1 May 2019 Medicines Update: Nerlynx - Puma Biotechnology A new medicine shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer has been approved by the TGA for use in Australian patients. Nerlynx (neratinib) is an oral medication taken for 12 months by women
- [Pharma in Focus: 14 May, 2019](https://stabiopharma.com/pharma-in-focus-14-may-2019/) - PHARMA IN FOCUS By Megan Brodie 14 May 2019 PBAC System Labelled 'Broken' Australia's reimbursement process for listing new drugs is broken and Australia is now on the precipice of missing out on new drugs, Specialised Therapeutics Australia CEO Carlo Montagner has warned. Companies spend millions of dollars and take years to get a new
- [Weekend Australian: 11 May, 2019](https://stabiopharma.com/weekend-australian-11-may-2019/) - Weekend Australian By Sarah-Jane Tasker 11 May 2019 Speed Up Cancer Funding, ALP Told The head of Australian drug company Specialised Therapeutics, Carlo Montagner, has warned that Bill Shorten’s cancer policy will not hit its target unless he overhauls the process to reimburse lifesaving treatments and puts a time frame on listing recommended drugs. Mr
- [Channel 9 News: June 2019](https://stabiopharma.com/channel-9-news-june-2019/) - The following news clip appeared on National Nine News. Click to view.
- [Pharma in Focus: 17 May, 2019](https://stabiopharma.com/pharma-in-focus-17-may-2019/) - PHARMA IN FOCUS By Megan Brodie 17 May 2019 Drugs to be Tracked End-to-End Local pharma Specialised Therapeutics Australia (STA) has launched a tracking system that will enable real time monitoring of its drug products as they move through the supply chain, while also making the practice of vial sharing more difficult. The company has
- [The Daily Telegraph: 22 February, 2020](https://stabiopharma.com/the-daily-telegraph-22-february-2020/) - THE DAILY TELEGRAPH By Sue Dunlevy 22 February 2020 Tussle over cancer test Rejection angers support group A $5000 test that can indicate whether a breast cancer patient needs chemotherapy has been rejected for a government subsidy, even though it would mean thousands of women could avoid the harrowing treatment. The government’s Medical Services Advisory
- [Pharma Dispatch: 16 April, 2020](https://stabiopharma.com/pharma-dispatch-16-april-2020/) - Pharma Dispatch 16 April 2020 STA: New fees a "major barrier" to patient access Specialised Therapeutics Australia says proposed further increases in PBS submission and listing fees are "prohibitive" for smaller companies and risk becoming a "major barrier" to patient access to new medicines. The Department of Health recently announced new and higher cost recovery
- [The Courier Mail: 22 February, 2020](https://stabiopharma.com/the-courier-mail-22-february-2020/) - THE COURIER MAIL By Sue Dunlevy 22 February 2020 Breast cancer test fail Government denies funding to help avoid chemo A $5000 test that can indicate whether a breast-cancer patient needs chemotherapy has been rejected for a government subsidy even though it could potentially save thousands of women from having to undergo the harrowing cancer
- [Pharma in Focus: 16 April, 2020](https://stabiopharma.com/pharma-in-focus-16-april-2020/) - PHARMA IN FOCUS By Megan Brodie 16 April 2020 PBAC fees too high for little guy The owner of Australia's largest independent pharmaceutical company says changes to PBAC fees mean small companies need to budget almost $2 million to make a submission for a medicine to be listed on the PBS, with no guarantee of
- [EOC Award: CEO Comment](https://stabiopharma.com/eoc-award-ceo-comment/) - Watch Video Click on the video banner above to watch CEO Carlo Montagner discuss STA's 2020 Employer of Choice award on Ticker News. For more information visit https://employerofchoiceawards.com.au/eoc-winners-2020/specialised-therapeutics-2020-eoc/
- [Channel 10 News: December 2020](https://stabiopharma.com/channel-10-news-december-2020/) - The following stories appeared on Channel 10 News and other news outlets nationally. Click on the thumbnails below to view them. Breast Surgeon Dr Jane O'Brien on Channel 10 News Breast Cancer Surgeon Dr Chantel Thornton on ABC News Breast Cancer Surgeon Dr Chantel Thornton on 7 News Breast Surgeon Dr Jane O'Brien on
- [Australian Financial Review: 15 March, 2021](https://stabiopharma.com/australian-financial-review-15-march-2021/) - Australian Financial Review By Carrie LaFrenz 15 March 2021 Latitude Offers Payment Plans for $5000 Breast Cancer Test When Carlo Montagner – the founder of Australia’s largest independent specialist pharmaceutical company – was buying a new sofa at Harvey Norman he saw a Latitude Financial Group sign, and it sparked an idea. A year on, his
- [Oral Mucositis - Expert Opinion, Prof Dorothy Keefe](https://stabiopharma.com/oral-mucositis-expert-opinion-prof-dorothy-keefe/) - "Oral mucositis is quite debilitating, because pain in your mouth, or ulceration in your mouth, makes it hard to eat and to swallow." “Pretty much every cancer agent can cause some degree of mouth or gut damage. But it all depends on which drugs and what doses you are using. The range of incidence is
- [Brain Tumour Awareness Month 2020: Introducing Vanessa](https://stabiopharma.com/brain-tumour-awareness-month-2020-introducing-vanessa/) - In Brain Tumour Awareness Month, we are recognising passionate people who are making a difference in brain cancer. Vanessa van den Berg is a senior ST brand manager, responsible for marketing several products in oncology and haematology. But, she has a very personal reason for making a difference in brain cancer. “I’m a strong
- [Sarcoma Awareness Month: Dr Ganessan Kichenadasse](https://stabiopharma.com/sarcoma-awareness-month-dr-ganessan-kichenadasse/) - Immunotherapy drugs used as single agent therapies are so far showing little effect in treating sarcomas, according to an Adelaide-based sarcoma specialist, Dr Ganessan Kichenadasse. He says that while there have been some positive steps forward in treating sarcomas in the past 20 years, there is much more to be achieved. Dr Kichenadasse predicts the
- [New Deal: ST signs new license agreement](https://stabiopharma.com/new-deal-st-signs-new-license-agreement/) - ST has signed a third license agreement with Spanish partner PharmaMar, providing Australian patients the opportunity to access a globally-recognised sarcoma therapy. Click for more.
- [Breast Surgeon Jane O’Brien discusses Oncotype DX](https://stabiopharma.com/breast-surgeon-jane-obrien-discusses-oncotype-dx/) - Respected Australian breast cancer surgeon Jane O’Brien discusses the Oncotype DX breast cancer assay. Click on the video banner above for more.
- [New Drug To Fight Hospital Superbug Infection](https://stabiopharma.com/new-drug-to-fight-hospital-superbug-infection/) - Melbourne, Australia , 20 June 2012 - A new therapy to treat a common hospital superbug* infection Clostridium difficile, will soon be available to Australian & New Zealand patients. Melbourne biopharmaceutical company Specialised Therapeutics Australia Pty, Ltd. (STA) has entered into an exclusive distribution & license agreement with US based Optimer Pharmaceuticals, Inc. (Optimer) to develop and
- [Biospace: 16 July, 2020](https://stabiopharma.com/biospace-16-july-2020/) - BIOSPACE 16 July 2020 New Early Breast Cancer Drug Now Approved in Malaysia SINGAPORE, July 16, 2020 /PRNewswire/ -- A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have
- [ST sponsors Jomar Life Research](https://stabiopharma.com/st-sponsors-jomar-life-research/) - ST is proud to sponsor events and causes aligned with our mission. We were recognised as platinum sponsors of Jomar Life Research as it navigated the 2018 Mystery Box Rally - a 2500 kilometre outback adventure raising money for cancer research. Behind the wheel? Jomar employees Sarah Fardy and Sue Ang,who navigated the treacherous adventure
- [10 Years of ABRAXANE in Australia](https://stabiopharma.com/10-years-of-abraxane-in-australia/) - STA was founded in 2008 with a single oncology product, a chemotherapy drug called ABRAXANE. It was not yet approved to treat pancreatic cancer anywhere in the world, but Perth oncologist Dr Andrew Dean had heard promising data about this new medicine at an international scientific meeting. At the same time, he was quietly contemplating
- [From the CEO](https://stabiopharma.com/from-the-ceo/) - Paul Cross is a former Federal Government ministerial advisor and senior pharma executive. Since 2012, he has been the publisher and editor-in-chief of three daily digital news mastheads covering policy, funding and politics in the Australian life-sciences sector, PharmaDispatch, BiotechDispatch and HealthDispatch. His independent news services have around 12,000 subscribers. He sat down with Carlo
- [Where it all began: How 007 became ABRAXANE](https://stabiopharma.com/where-it-all-began-how-007-became-abraxane/) - It was 1992. The year that the space shuttle Endeavour made a successful mission to space, when the Cold War came to an end and when a Frenchman called George Charpak took out a Nobel prize in Physics for his inventions of particle detectors. It was also the year a new cancer drug called Taxol
- [TLC Ambulance Project: Another Special Memory Created](https://stabiopharma.com/tlc-ambulance-project-another-special-memory-created/) - ST's family office, the Montagner-Zembrzuski Family Foundation, is so proud to be one of the foundation sponsors of the TLC Ambulance Project, which is an amazing initiative to help desperately-ill children travel take a special journey of their own choice. These destinations are often not that fancy, but might even be a drive past their
- [Pharma Dispatch: 6 November, 2020](https://stabiopharma.com/pharma-dispatch-6-november-2020/) - PHARMADISPATCH 6 November 2020 Australians Will Need to 'Reconcile Themselves to this New Reality' November 6, 2020 -- Privately owned Australian pharmaceutical company Specialised Therapeutics Asia has signed an exclusive distribution agreement for a new therapy to treat advanced gastrointestinal stromal tumours (GIST). The agreement with US-based Deciphera Pharmaceuticals covers the commercialisation of switch-control tyrosine kinase
- [Pharma in Focus: 15 March, 2021](https://stabiopharma.com/pharma-in-focus-15-march-2021/) - PHARMA IN FOCUS By Nick Lush 15 March 2021 Is This a Funding Breakthrough? With the Zimmerman inquiry being told the PBAC is not up to scratch on delivering medicines to Australian patients, a 'thinking outside the square' option being pioneered by local pharmaSpecialised Therapeutics (STA) appears to be blazing a new funding trail. STA
- [Pharma Dispatch: 15 March, 2021](https://stabiopharma.com/pharma-dispatch-15-march-2021/) - BioPharma Dispatch 15 March 2021 Australians Will Need to 'Reconcile Themselves to this New Reality' STA's Carlo Montagner says the company's finance arrangement with Latitude Finance to support patient access to a cancer recurrence diagnostic is unfortunate but that Australians need to "reconcile themselves to this new reality" while government funding remains such a challenge.
- [ST Asia Executive Appointments](https://stabiopharma.com/st-asia-executive-appointments/) - Singapore, 23 July 2020: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) has appointed two senior executives to its Singapore team, as it drives commercialisation of new oncology products in the region. Dr Bhuvana Ramaswamy will commence as Senior Medical Advisor for South East Asia in October, bringing extensive oncology, scientific and pharmaceutical industry expertise to the
- [Purple: Pancreatic Cancer Conversations Issue #1](https://stabiopharma.com/purple-pancreatic-cancer-conversations-issue-1/) - Click on the cover image to see inside Purple, a magazine produced by Specialised Therapeutics for pancreatic cancer patients. Thanks to all patients, families and clinicians who provided their stories and insights.
- [HCP News Template](https://stabiopharma.com/hcp-news-template/) - Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

## Pages

- [Homepage](https://stabiopharma.com/) - We collaborate with global partners to bring new specialist medicines to patients in Australia, New Zealand and SE Asia.
- [About Us](https://stabiopharma.com/about-us/) - About Founders Careers With the highest professional and ethical standards, we commercialise therapies and technologies that uniquely fulfil the unmet medical needs of our community. Specialised Therapeutics is an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East Asia. We partner with global pharmaceutical companies to champion their products
- [Products](https://stabiopharma.com/products/) - Oncology Endocrinology Haematology Neurology Opthalmology Genomic Assays Resources Australia Approved Product Information Consumer Medicine Information New Zealand Approved Data Sheet Consumer Medicine Information Resources Australia Approved Product Information Consumer Medicine Information Malaysia Approved Product Information Consumer Medicine Information New Zealand Approved Data Sheet Consumer Medicine Information Singapore Approved Product Information Thailand Approved Product Information Consumer
- [Pipeline](https://stabiopharma.com/pipeline/) - Pipeline ONCOLOGY ENDOCRINOLOGY HAEMATOLOGY OPHTHALMOLOGY NEUROLOGY P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval ZYNYZ® (retifanlimab) P1 P2 P3 RF Merkel Cell Carcinoma 100% 100% Non Small Cell Lung Cancer 100% 100% 100% Squamous Cell Carcinoma of the Anal Canal 100% 100% 100% ZEPZELCA™ (lurbinectedin) P1 P2 P3 RF 2nd Line Small Cell
- [Press Room](https://stabiopharma.com/news-and-resources/press-room/) - News Archive Press Releases Press Room ST Patient Magazines Load More
- [Press Releases](https://stabiopharma.com/news-and-resources/press-releases/) - News Archive Press Releases Press Room ST Patient Magazines Load More
- [News Archive](https://stabiopharma.com/news-and-resources/news-archive/) - News Archive Press Releases Press Room ST Patient Magazines Load More
- [ST Patient Magazines](https://stabiopharma.com/news-and-resources/st-patient-magazines/) - News Archive Press Releases Press Room ST Patient Magazines Load More
- [Contact us](https://stabiopharma.com/contact-us/) - Contact Us Global Headquarters & SE Asia Specialised Therapeutics Asia Pte Ltd Singapore (HQ) Address: 1 Harbourfront Avenue #14-03/07 Keppel Bay Tower Singapore 098632 T: +65 3158 9940 E: info@stbiopharma.com Vietnam Address: Serepok Tower, No. 56, Nguyen Dinh Chieu Street, Dakao Ward, District 1, Ho Chi Minh City, Vietnam T: +84 1203 2685 E: info@stbiopharma.com Thailand Address:
- [Oncotype DX breast recurrence score](https://stabiopharma.com/oncotype-dx-breast-recurrence-score-2/) - Oncotype DX Breast Recurrence Score® Further Information for Patients Oncotype DX Patient Education Booklet Further Information for Health Care Professionals International Pathology Guidelines Sample Oncotype DX Reports Node-Negative Report Understanding the Node Negative Report Node-Positive Report (1-3 nodes) Understanding the Node Positive Report For further information on how to order Oncotype DX, please contact
- [Annual Updates](https://stabiopharma.com/news-and-resources/annual-updates/) - News Archive Press Releases Press Room Submissions Annual Updates ST Patient Magazines Load More
- [Submissions](https://stabiopharma.com/news-and-resources/submissions/) - News Archive Press Releases Press Room Submissions Annual Updates ST Patient Magazines Load More
- [Oncotype DX Breast Recurrence Score Latitude](https://stabiopharma.com/oncotype-dx-breast-recurrence-score-latitude/) - 6 to 24 months Interest Free Payment Plans available on a Latitude Gem Visa credit card* Also available on other participating Latitude credit cards. For eligible purchases above a minimum financed amount using an Equal Monthly Payment Plan. T&Cs and monthly credit card fee (currently $10.95) will apply. Other credit card fees and charges may
- [Oncotype dx breast recurrence score payment](https://stabiopharma.com/oncotype-dx-breast-recurrence-score-payment/) - Please select your preferred payment option EFT Direct Debit Click here for this option Online Payment Click here for this option Interest-Free Payment Plans* Click here for this option * Credit provided by Latitude Finance Australia (ABN 42 008 583 588), Australian Credit Licence 392145. more info Requisition Form
- [Oncotype DX<sup>®</sup> breast recurrence score](https://stabiopharma.com/oncotype-dx-breast-recurrence-score/) - To order an Oncotype DX test, please complete the requisition form (doctors only) and the payment form (patients only) by selecting the relevant option below. Further Information for Prescribers and Patients Click to view Requisition Form for Doctors Click to view Payment Options Click to view Credit provided by Latitude Finance Australia (ABN 42 008 583
- [Administrator – New Account Registered](https://stabiopharma.com/administrator-new-account-1/) - Return to Administrator Menu
- [Orders – Retrieve Password](https://stabiopharma.com/order-forgot-pwd-1/)
- [Partnering](https://stabiopharma.com/partnering/) - Partnering Why Partner with Specialised Therapeutics? We take care of your product as if it were our own. We manage the regulatory and reimbursement complexities to ensure our partner’s drugs are commercialised to the highest standards. Track Record Specialised Therapeutics has a strong track record championing partner products from pre-registration through to full commercialisation. Regional
- [Philanthropy](https://stabiopharma.com/philanthropy/) - Philanthropy Giving ST was founded in 2008 by Carlo Montagner and Bozena Zembrzuski. Since then, it has evolved to become the largest independent pharmaceutical company in Australia. This corporate success is underpinned by a philanthropic mindset, and an enduring commitment to support causes that are synergistic with both our business and the philosophies of our
- [STA 10 Years](https://stabiopharma.com/sta-10-years/) - Celebrating 10 Years | Federal Treasurer Josh Frydenberg has officially opened our new Australian headquarters and toasted ST’s success in the past decade. The political heavyweight further praised ST’s culture of innovation and noted the significant contribution it had made to Australian healthcare. Click on the video above to watch our celebrations unfold. Load More
- [Shop](https://stabiopharma.com/shop/)
- [Sample Page](https://stabiopharma.com/sample-page/) - Load More
- [Orders Login](https://stabiopharma.com/order-login/)
- [ANNIKO (penpulimab)](https://stabiopharma.com/hcp_anniko/)
- [ PEMAZYRE (pemigatinib)](https://stabiopharma.com/hcp_pemazyre/) - Optimising Molecular Pathology in Cholangiocarcinoma Pathologist’s Perspective Oncologist’s Perspective Surgeon’s Perspective
- [Oncotype Info Page](https://stabiopharma.com/oncotype-info-page/) - Quotes from the above video are referenced at the bottom of this page The Oncotype DX® Breast Cancer Assay provides patients and their physicians with individualised information about their breast cancer to guide decisions on how to proceed with treatment. When someone is diagnosed with early-stage breast cancer, the first step is usually surgery to remove
- [Terms and Conditions](https://stabiopharma.com/terms-and-conditions/) - Terms and Conditions for the Use of www.stabiopharma.com and www.stbiopharma.com Conditions of Use Please read these Terms of Use and Privacy Policy carefully. By proceeding to access and use this site, you are agreeing to these terms. All contents, including text and images, are the property of Specialised Therapeutics and/or its affiliates, and may not
- [Orders - Change Password](https://stabiopharma.com/order-change-pwd/) - Back to Menu
- [Orders - Terms and Conditions](https://stabiopharma.com/order-term-conditions/) - THE ST GROUP TERMS AND CONDITIONS OF TRADE (AUSTRALIA) 1. Definitions In these Terms: ACL means the Australian Consumer Law Schedule of the Competition and Consumer Act 2010 (Cth) and its associated Regulations as amended; Agreement means any agreement for the provision of goods or services by the applicable member of the ST
- [Orders - Terms and Conditions](https://stabiopharma.com/orders-terms-and-conditions/) - Please read these Terms of Use and Privacy Policy carefully. By proceeding to access and use this site, you are agreeing to these terms. All contents, including text and images, are the property of Specialised Therapeutics Australia. and/or its affiliates, and may not be downloaded, stored, reposted, modified, distributed or otherwise used except as provided
- [Specialised Therapeutics Corporate Support](https://stabiopharma.com/philanthropy/specialised-therapeutics-corporate-support/) - One of our key company values is Humanity and it’s our endeavour to embody and embed this quality in all parts of our business. As part of this, ST is proud and committed to supporting a range of organisations and charities that are aligned with our healthcare business. Since our inception, we have donated more
- [Orders - Menu](https://stabiopharma.com/order-menu/) - Welcome Change Password Change Account Details Order Online (Oncotype) Order Online (other products) View Placed Orders Terms & Conditions for Online Ordering
- [Orders - View Placed Orders](https://stabiopharma.com/order-view-order-list/) - Back to Menu
- [Orders - View Placed Orders](https://stabiopharma.com/order-view-order-list-1/) - Back to Menu
- [Orders - New Order (Submitted)](https://stabiopharma.com/order-online-2/) - Back to Menu
- [Orders - New Order (Shipping Detail)](https://stabiopharma.com/order-online-1/) - Back to Menu
- [Orders - New Order](https://stabiopharma.com/order-online/) - Back to Menu
- [Orders - Change Password Status](https://stabiopharma.com/order-change-pwd-1/) - Back to Menu
- [Orders - Change Account Details Status](https://stabiopharma.com/order-change-detail-1/) - Back to Menu
- [Orders - Change Account Details](https://stabiopharma.com/order-change-detail/) - Back to Menu
- [Administrator Menu](https://stabiopharma.com/administrator-menu/) - Add New Customer / Account Approve Customer / Account Edit Customer / Account Detail Export Mailing List Export Customer Detail to CVS View / Edit Order List Export Order to CVS
- [Administrator - View Order List](https://stabiopharma.com/administrator-view-order/) - Return to Administrator Menu
- [Administrator - View Customer List](https://stabiopharma.com/administrator-view-customer-list/) - Return to Administrator Menu
- [Administrator - Update Order Detail](https://stabiopharma.com/administrator-edit-order-1/) - The order detail has been successfully updated. Return to Administrator Menu
- [Administrator - Update Customer Detail](https://stabiopharma.com/administrator-view-customer-list-2/) - The account has been successfully updated. Return to Administrator Menu
- [Administrator - New Account List for Approval](https://stabiopharma.com/administrator-account-approval/) - Return to Administrator Menu
- [Administrator - New Account for Approval Status](https://stabiopharma.com/administrator-account-approval-2/) - Return to Administrator Menu
- [Administrator - New Account for Approval](https://stabiopharma.com/administrator-account-approval-1orders-2/) - Return to Administrator Menu
- [Administrator - New Account](https://stabiopharma.com/administrator-new-account/) - Return to Administrator Menu
- [Administrator - Export Order to CSV File](https://stabiopharma.com/administrator-export-order/) - Return to Administrator Menu
- [Administrator - Export Email List](https://stabiopharma.com/administrator-export-email1/) - Return to Administrator Menu
- [Administrator - Export Email](https://stabiopharma.com/administrator-export-email/) - Return to Administrator Menu
- [Administrator - Export Customer Detail to CVS](https://stabiopharma.com/administrator-export-detail/) - Return to Administrator Menu
- [Administrator - Export Customer Detail to CSV File](https://stabiopharma.com/administrator-export-detail-1/) - Return to Administrator Menu
- [Administrator - Edit Order](https://stabiopharma.com/administrator-edit-order/) - Return to Administrator Menu
- [Administrator - Edit Customer Detail](https://stabiopharma.com/administrator-view-customer-list-1/) - Return to Administrator Menu
- [Administrator Login](https://stabiopharma.com/administrator-login/)
- [Orders - Forgot Password](https://stabiopharma.com/order-forgot-pwd/)
- [Montagner Zembrzuski Family Foundation](https://stabiopharma.com/philanthropy/montagner-zembrzuski-family-foundation/) - We established the Montagner-Zembrzuski Family Foundation in 2015 as a family office dedicated to making a difference to causes big and small that could benefit from our support. But our commitment to giving was cemented well before the family office was founded. Like many others, our family has also been affected by cancer. When the
- [Orders](https://stabiopharma.com/orders/) - test
- [HCP Portal Test](https://stabiopharma.com/hcp-portal-test/) - Resources Name of the Resource Item 1 Name of the Resource Item 1 Videos [video_lightbox_youtube video_id="Rb4gkVr0zh0" width="1920" height="1080" anchor="https://stabiopharma.com/wpstabio/wp-content/uploads/2021/05/v-partnering-collaborate-320x220.jpg"] Title of Video 1 Short Description of video1 [video_lightbox_youtube video_id="7kMFgoMZmMg" width="1920" height="1080" anchor="https://stabiopharma.com/wpstabio/wp-content/uploads/2021/05/v-partnering-takeda-320x220.jpg"] Title of Video 2 Short Description of video2
- [Site Map](https://stabiopharma.com/site-map/) - Home About About Us Founder Careers STA 10 Years Philanthropy Products Pipeline Partnering News and Resources News Archive Press Releases Press Room Submissions CEO Blog Annual Updates ST Patient Magazines Orders Contact Us
- [Privacy Policy](https://stabiopharma.com/privacy-policy-2/) - Please click on the link below to view our Privacy Policy. Read Privacy Policy
- [News Archive Test](https://stabiopharma.com/news-archive-test/) - nick.c@ekkodesign.com.au Text Button Text Button
- [News and Resources](https://stabiopharma.com/news-and-resources/) - March 12, 2021 Hello world! by stabioadmin | 1 Comment Read More March 29, 2021 The Title Of The News Article Appear Here by stabioadmin | 0 Comments Australia’s new Federal Treasurer Josh Frydenberg officially unveiled ST’s new Melbourne headquarters, an event coinciding with the company’s ... Read More April 5, 2021 Oncotype DX –

## Media Hub

- [Yorvipath – Prof Aliya Khan Provides Expert Insights](https://stabiopharma.com/media/10903/)
- [Yorvipath – Expert Panel Q&A Session at the ST Educational Symposium – Insights from ESA-ANZBMS 2024](https://stabiopharma.com/media/10922/)
- [Yorvipath – Prof David Torpy – The Australian Patient Experience with Chronic Hypoparathyroidism](https://stabiopharma.com/media/10918/)
- [Yorvipath - A/Prof Cherie Chiang Presents 3-Year Bone Data](https://stabiopharma.com/media/10915/)

## Services

- [Access Programs](https://stabiopharma.com/services/access-programs/) - STA successfully launches and manages Named Patient Access Programs in our regions, enabling patients early or compassionate access to new therapies.
- [Reimbursement Expertise](https://stabiopharma.com/services/reimbursement-expertise/) - Our experienced teams navigate reimbursement applications and processes for pharmaceutical products, companion diagnostics and other medical technologies.
- [Commercialisation](https://stabiopharma.com/services/commercialisation/) - STA achieves rapid market penetration and leadership of portfolio therapies.
- [Regulatory](https://stabiopharma.com/services/regulatory/) - STA regulatory teams manage complex submission processes in all key markets, including Orphan and Fast-Track designations.
- [Agreements](https://stabiopharma.com/services/agreements/) - STA is open to joint ventures, typical royalty and milestone-based licensing agreements or other creative, mutually beneficial partnering opportunities.

## Teams

- [Becky Jasmine](https://stabiopharma.com/teams/becky-jasmine/)
- [Richards](https://stabiopharma.com/teams/richards/)
- [Emali Cruz](https://stabiopharma.com/teams/emali-cruz/)
- [STEFHEN JOE](https://stabiopharma.com/teams/stefhen-joe/)

## Timeline

- [New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS](https://stabiopharma.com/timeline/new-chemotherapy-free-immunotherapy-combination-for-follicular-lymphoma-listed-on-the-pbs/) - The PBS listing of Minjuvi marks the availability of the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen funded in Australia for this group of patients.
- [ST Expands Partnership with Incyte](https://stabiopharma.com/timeline/st-expands-partnership-with-incyte-2/) - Specialised Therapeutics Expands Partnership with Incyte to Include Opzelura.
- [ST has been recognised as a Great Place To Work® Australia for the 4th consecutive year](https://stabiopharma.com/timeline/st-has-been-recognised-as-a-great-place-to-work-australia-for-the-4th-consecutive-year/) - "Together, we continue to foster an environment where people feel supported, empowered and inspired to make a meaningful difference for patients." - Carlo Montagner, CEO
- [New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia](https://stabiopharma.com/timeline/new-first-in-class-therapy-for-chronic-graft-versus-host-disease-approved-in-australia/) - NIKTIMVO was assessed through the TGA’s Priority Review pathway and is the first approved anti-colony stimulating factor-1 receptor (anti-CSF-1R) antibody for cGVHD.
- [ST Expands Partnership with Incyte](https://stabiopharma.com/timeline/st-expands-partnership-with-incyte/) - Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
- [New Breast Cancer Therapy](https://stabiopharma.com/timeline/new-breast-cancer-therapy/) - To Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
- [MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia](https://stabiopharma.com/timeline/minjuvi-tafasitamab-for-relapsed-or-refractory-follicular-lymphoma-approved-in-australia/) - The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients.
- [ST – Ascendis Pharma Partnership](https://stabiopharma.com/timeline/st-ascendis-pharma-partnership/) - Specialised Therapeutics Signs Exclusive Agreement With Ascendis Pharma For Three Endocrinology Therapies
- [ST – Canaria Bio Partnership](https://stabiopharma.com/timeline/st-canaria-bio-partnership/) - Specialised Therapeutics signed partnership agreement with Canaria Bio to commercialise Oregovomab in Australia, New Zealand and select Southeast Asia countries.
- [ST – World Orphan Drug Alliance (WODA) Partnership](https://stabiopharma.com/timeline/st-world-orphan-drug-alliance-woda-partnership/) - Specialised Therapeutics joins the World Orphan Drug Alliance representing Australia, New Zealand and Southeast Asia (ANZSEA).
- [ST – Treeway BV Partnership](https://stabiopharma.com/timeline/st-treeway-bv-partnership/) - Specialised Therapeutics signs partnership agreement with Treeway BV to commercialise Edaravone in Australia and New Zealand.
- [ST – Akeso Inc. Partnership](https://stabiopharma.com/timeline/st-akeso-inc-partnership/) - Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia.
- [Thailand Office Opened](https://stabiopharma.com/timeline/thailand-office-opened/) - ST established a representative office in Thailand, amid growing demand for specialist therapies in the region.
- [Vietnam Office Opened](https://stabiopharma.com/timeline/vietnam-office-opened/) - ST established a representative office in Vietnam, to accommodate a growing regional presence.
- [Alimera Sciences, Inc. Partnership](https://stabiopharma.com/timeline/alimera-sciences-inc-partnership/) - ST partners with US-based Alimera Sciences, Inc. for exclusive rights to distribute ILUVIEN® (190 micrograms fluocinolone acetonide intravitreal implant in applicator) in Australia and New Zealand
- [ST wins PRIME Healthcare Award](https://stabiopharma.com/timeline/st-wins-prime-healthcare-award/) - ST awarded a prestigious PRIME Healthcare Award for Excellence in Patient or Customer Support for NERLYNX® Patient Support Program
- [ST 10 Year Anniversary](https://stabiopharma.com/timeline/st-10-year-anniversary/) - ST celebrated its first decade in business, unveiling new Melbourne office in a ceremony led by Australian Federal Treasurer Josh Frydenberg MP.
- [ABRAXANE<sup>®</sup> Reimbursed](https://stabiopharma.com/timeline/abraxane-reimbursed-metastatic-breast-cancer/) - ABRAXANE® (nanoparticle albumin-bound paclitaxel) reimbursed in Australia for metastatic breast cancer (mBc)
- [ST-Incyte Partnership Agreement](https://stabiopharma.com/timeline/st-incyte-partnership-agreement/) - ST partners with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios
- [ST – Onconova Therapeutics  Partnership](https://stabiopharma.com/timeline/st-onconova-therapeutics-partnership/) - ST partners with US-based Onconova Therapeutics, acquiring exclusive rights to market Rigosertib in Australia and New Zealand
- [ABRAXANE® reimbursed for metastatic pancreatic cancer (mPc)](https://stabiopharma.com/timeline/abraxane-reimbursed-for-metastatic-pancreatic-cancer-mpc/) - ST achieves a further PBS listing for ABRAXANE® in metastatic pancreatic cancer
- [ABRAXANE<sup>®</sup> reimbursed for metastatic pancreatic cancer (mPc)](https://stabiopharma.com/timeline/abraxane-reimbursed-for-metastatic-pancreatic-cancer-mpc/) - ST achieves a further PBS listing for ABRAXANE® in metastatic pancreatic cancer
- [Optimer Pharmaceuticals, Inc. Partnership](https://stabiopharma.com/timeline/optimer-pharmaceuticals-inc-partnership/) - ST partners with US-based biopharmaceutical company Optimer Pharmaceutics, Inc. acquiring exclusive rights to market DIFICID® (fidaxomicin) in Australia and New Zealand
- [Ariad Pharmaceuticals Partnership](https://stabiopharma.com/timeline/aloxi-reimbursement/) - US-based Ariad Pharmaceuticals grants ST exclusive rights to market ICLUSIG® (ponatinib) in Australia, NZ
- [Genomic Health Partnership](https://stabiopharma.com/timeline/aloxi-registration/) - ST partners with US company Genomic Health to market the Oncotype DX Breast Recurrence Score® test
- [AKYNZEO<sup>®</sup> Acquired](https://stabiopharma.com/timeline/akynzeo-acquired/) - ST acquires AKYNZEO® (netupitant) under exclusive license from Helsinn Healthcare
- [Photonamic GmbH and co Partnership](https://stabiopharma.com/timeline/market-share-leadership-in-mbc-taxane-market-segment1/) - ST acquires exclusive rights to market brain tumour visualisation technology GLIOLAN® (animolivulenic acid hcl) in Australia, New Zealand
- [ST Founded](https://stabiopharma.com/timeline/our-history/) - ST establishes office in Melbourne, Australia
- [ST acquires rights to market YONDELIS<sup>®</sup> (trabectedin) in Australia, NZ and South East Asia](https://stabiopharma.com/timeline/st-acquires-rights-to-market-yondelis-trabectedin-in-australia-nz-and-south-east-asia/) - ST signs further licensing agreement with Spanish partner PharmaMar
- [ST - Abraxis Bioscience Partnership](https://stabiopharma.com/timeline/february/) - ST acquires exclusive Australian rights to market foundation product ABRAXANE® (nanoparticle-albumin bound paclitaxel)
- [ST-Helsinn Healthcare Partnership](https://stabiopharma.com/timeline/abraxane-metastatic-breast-cancer-mbc-registration/) - ST partners with privately-owned Swiss pharma company Helsinn Healthcare, acquiring exclusive rights to anti-nausea drug ALOXI® (palonesetron) in Australia and NZ
- [ST PharmaMar SA Partnership](https://stabiopharma.com/timeline/st-pharmamar-sa-partnership/) - ST partners with Spanish company PharmaMar SA, acquiring exclusive rights to APLIDIN® (plitidepsin) in Australia, New Zealand and South East Asia
- [ST – Puma Biotechnology Partnership](https://stabiopharma.com/timeline/st-puma-biotechnology-partnership/) - ST partners with US-based Puma Biotechnology, acquiring exclusive rights to market NERLYNX® (neratinib) in Australia, NZ and South-East Asia
- [ALOXI<sup>®</sup> Reimbursed](https://stabiopharma.com/timeline/mbc-reimbursement/) - ST achieves PBS reimbursement for ALOXI® (palonosetron)
- [ICLUSIG<sup>®</sup> (ponatinib) Reimbursed for Chronic Myeloid Leukaemia (CML)](https://stabiopharma.com/timeline/iclusig-ponatinib-reimbursed-for-chronic-myeloid-leukaemia-cml/) - ST achieves PBS reimbursement for ICLUSIG® (ponatinib) in Australia
- [ST acquires rights to anti-cancer compound ZEPZELCA<sup>®</sup> (lurbinectedin)](https://stabiopharma.com/timeline/st-acquires-rights-to-anti-cancer-compound-zepzelca-lurbinectedin/) - ST signs a second major licensing deal with European pharmaceutical company PharmaMar.
- [ICLUSIG<sup>®</sup> achieves extended PBS listing](https://stabiopharma.com/timeline/iclusig-achieves-extended-pbs-listing/) - ST achieves further PBS reimbursement for ICLUSIG® in PH+ Acute Lymphoblastic Leukaemia (ALL)
- [ST-Deciphera Pharmaceuticals Partnership](https://stabiopharma.com/timeline/st-deciphera-pharmaceuticals-partnership/) - ST partners with US based Deciphera Pharmaceuticals, acquiring exclusive rights to market QINLOCK® (ripretinib) in Australia, NZ and South East Asia
- [NERLYNX<sup>®</sup> (neratinib) approved in Singapore for extended adjuvant therapy in HER2+/HR+ breast cancer](https://stabiopharma.com/timeline/nerlynx-neratinib-approved-in-singapore-for-extended-adjuvant-therapy-in-her2-hr-breast-cancer/) - ST achieves approval to market NERLYNX® (neratinib) in Singapore for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
- [ST named 2020 Employer of Choice](https://stabiopharma.com/timeline/st-named-2020-employer-of-choice/) - ST recognised as an Employer of Choice in prestigious national business awards.

## Shortcodes

- [Our History - Horizontal](https://stabiopharma.com/?wptl_scbd=our-history-horizontal)

## KC Sections

- [Partnering Page](https://stabiopharma.com/kc-section/partnering-page/) - Why Partner with Specialised Therapeutics? We take care of your product as if it were our own. We manage the regulatory and reimbursement complexities to ensure our partner’s drugs are commercialised to the highest standards. Track Record Specialised Therapeutics has a strong track record championing partner products from pre-registration through to full commercialisation. Regional Expertise
- [HCP Resources Tempalte](https://stabiopharma.com/kc-section/hcp-resources-tempalte/) - Resources Name of the Resource Item 1 Name of the Resource Item 2 Videos Title of Video 1 Short Description of the Video 1 Title of Video 2 Short Description of Video2
- [News Resources](https://stabiopharma.com/kc-section/news-resources/) - News Archive Press Release Press Room Submission CEO Blog Annual Updates ST Patients Magazine April 5, 2021 Oncotype DX – Maxine Gladwin’s Experience by stabioadmin | 0 Comments Maxine Gladwin was 47 and single mum to three teenage daughters when she was diagnosed with breast cancer. ... Read More April 5, 2021 Introducing GIST and
- [Product](https://stabiopharma.com/kc-section/product/) - Oncology Haematology Neurosurgery Opthalmology Genomic Assays ABRAXANE® (nanoparticle albumin-bound paclitaxel) is used for the treatment of patients with: Metastatic breast cancer Non-small cell lung cancer, in combination with another cancer medicine, carboplatin Metastatic pancreatic cancer, in combination with another cancer medicine, gemcitabine Resources ABRAXANE Product Information (Australia) ABRAXANE Data Sheet (New Zealand) ABRAXANE Consumer Medicine
- [About Us](https://stabiopharma.com/kc-section/about-us/) - About Founders Careers With the highest professional and ethical standards, we commercialise therapies and technologies that uniquely fulfil the unmet medical needs of our community. Specialised Therapeutics is an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East Asia. We partner with global pharmaceutical companies to champion their products

## Categories

- [uncategorized](https://stabiopharma.com/category/uncategorized/)
- [Job Posting](https://stabiopharma.com/category/job-posting/)
- [Milestone And Events](https://stabiopharma.com/category/milestone-and-events/)
- [News Archive](https://stabiopharma.com/category/sidebarcategory/news-archive/)
- [Press Releases](https://stabiopharma.com/category/sidebarcategory/press-releases/)
- [Press Room](https://stabiopharma.com/category/sidebarcategory/press-room/)
- [ST Patients Magazines](https://stabiopharma.com/category/sidebarcategory/st-patients-magazines/)
- [SidebarCategory](https://stabiopharma.com/category/sidebarcategory/)
- [Hcp News](https://stabiopharma.com/category/hcp-news/)
- [Timeline](https://stabiopharma.com/category/timeline/)
- [Milestone And Events 1](https://stabiopharma.com/category/milestone-and-events/milestone-and-events-1/)
- [Milestone And Events 2](https://stabiopharma.com/category/milestone-and-events/milestone-and-events-2/)
- [Milestone And Events 3](https://stabiopharma.com/category/milestone-and-events/milestone-and-events-3/)
- [Milestone And Events 4](https://stabiopharma.com/category/milestone-and-events/milestone-and-events-4/)
- [mzff](https://stabiopharma.com/category/mzff/)
- [Partnering](https://stabiopharma.com/category/partnering/)
- [Specialised Therapeutics Corporate Support](https://stabiopharma.com/category/specialised-therapeutics-corporate-support/)
- [Nerlynx](https://stabiopharma.com/category/nerlynx/)
- [Nurse and Patients](https://stabiopharma.com/category/nerlynx/nurse-and-patients/)
- [A Global Perspective](https://stabiopharma.com/category/nerlynx/a-global-perspective/)
- [Latest News](https://stabiopharma.com/category/latest-news/)
- [Yondelis](https://stabiopharma.com/category/yondelis/)
- [Yorvipath](https://stabiopharma.com/category/yorvipath/)

## Tags

- [Yondelis](https://stabiopharma.com/tag/yondelis/)
- [Sarcoma](https://stabiopharma.com/tag/sarcoma/)
- [trabectedin](https://stabiopharma.com/tag/trabectedin/)
- [Zepzelca](https://stabiopharma.com/tag/zepzelca/)
- [lurbinectedin](https://stabiopharma.com/tag/lurbinectedin/)
- [small cell lung cancer](https://stabiopharma.com/tag/small-cell-lung-cancer/)
- [distributor](https://stabiopharma.com/tag/distributor/)
- [Tafasitamab](https://stabiopharma.com/tag/tafasitamab/)
- [Pemigatinib](https://stabiopharma.com/tag/pemigatinib/)
- [Australia](https://stabiopharma.com/tag/australia/)
- [New Zealand](https://stabiopharma.com/tag/new-zealand/)
- [Singapore](https://stabiopharma.com/tag/singapore/)
- [GIST](https://stabiopharma.com/tag/gist/)
- [qinlock](https://stabiopharma.com/tag/qinlock/)
- [logistics](https://stabiopharma.com/tag/logistics/)
- [breast cancer](https://stabiopharma.com/tag/breast-cancer/)
- [HER2+](https://stabiopharma.com/tag/her2/)
- [HR+](https://stabiopharma.com/tag/hr/)
- [Philippines](https://stabiopharma.com/tag/philippines/)
- [cholangiocarcinoma](https://stabiopharma.com/tag/cholangiocarcinoma/)
- [nerlynx](https://stabiopharma.com/tag/nerlynx/)
- [pharma](https://stabiopharma.com/tag/pharma/)
- [oncology](https://stabiopharma.com/tag/oncology/)
- [marinescience](https://stabiopharma.com/tag/marinescience/)
- [pbs](https://stabiopharma.com/tag/pbs/)
- [liposarcoma](https://stabiopharma.com/tag/liposarcoma/)
- [leiomyosarcoma](https://stabiopharma.com/tag/leiomyosarcoma/)
- [softtissuesarcoma](https://stabiopharma.com/tag/softtissuesarcoma/)
- [Yorvipath](https://stabiopharma.com/tag/yorvipath/)
- [Hypoparathyroidism](https://stabiopharma.com/tag/hypoparathyroidism/)
- [axatilimab](https://stabiopharma.com/tag/axatilimab/)
- [Niktimvo](https://stabiopharma.com/tag/niktimvo/)
- [retifanlimab](https://stabiopharma.com/tag/retifanlimab/)
- [Zynyz](https://stabiopharma.com/tag/zynyz/)
- [thailand](https://stabiopharma.com/tag/thailand/)
- [refractory follicular lymphoma](https://stabiopharma.com/tag/refractory-follicular-lymphoma/)
- [relapsed follicular lymphoma](https://stabiopharma.com/tag/relapsed-follicular-lymphoma/)
- [follicular lymphoma](https://stabiopharma.com/tag/follicular-lymphoma/)
- [Minjuvi](https://stabiopharma.com/tag/minjuvi/)
- [R/R FL](https://stabiopharma.com/tag/r-r-fl/)
- [graft-versus-host disease](https://stabiopharma.com/tag/graft-versus-host-disease/)
- [Chronic GVHD](https://stabiopharma.com/tag/chronic-gvhd/)
- [GVHD](https://stabiopharma.com/tag/gvhd/)
- [cGVHD](https://stabiopharma.com/tag/cgvhd/)
- [Immunotherapy](https://stabiopharma.com/tag/immunotherapy/)
- [inMIND](https://stabiopharma.com/tag/inmind/)
- [rituximab](https://stabiopharma.com/tag/rituximab/)
- [lenalidomide](https://stabiopharma.com/tag/lenalidomide/)
- [CD19](https://stabiopharma.com/tag/cd19/)
- [CD20](https://stabiopharma.com/tag/cd20/)

## Category

- [Our Teams](https://stabiopharma.com/team_category/our-teams/)

## Category

- [WhatWeDo](https://stabiopharma.com/services_category/whatwedo/)

## Category

- [History Timeline](https://stabiopharma.com/timeline-category/history-timeline/)
- [Partnering Timeline](https://stabiopharma.com/timeline-category/partnering-timeline/)